US20180251728A1 - Androgenetic haploid embryonic stem cell, and preparation method and use thereof - Google Patents
Androgenetic haploid embryonic stem cell, and preparation method and use thereof Download PDFInfo
- Publication number
- US20180251728A1 US20180251728A1 US15/740,974 US201515740974A US2018251728A1 US 20180251728 A1 US20180251728 A1 US 20180251728A1 US 201515740974 A US201515740974 A US 201515740974A US 2018251728 A1 US2018251728 A1 US 2018251728A1
- Authority
- US
- United States
- Prior art keywords
- dmr
- library
- semi
- cloned
- haescs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001671 embryonic stem cell Anatomy 0.000 title claims description 30
- 238000002360 preparation method Methods 0.000 title description 9
- 238000000034 method Methods 0.000 claims abstract description 105
- 241001465754 Metazoa Species 0.000 claims abstract description 92
- 210000000287 oocyte Anatomy 0.000 claims abstract description 49
- 238000010353 genetic engineering Methods 0.000 claims abstract description 12
- 108091027544 Subgenomic mRNA Proteins 0.000 claims description 144
- 108091033409 CRISPR Proteins 0.000 claims description 85
- 108090000623 proteins and genes Proteins 0.000 claims description 84
- 210000002257 embryonic structure Anatomy 0.000 claims description 56
- 239000013612 plasmid Substances 0.000 claims description 54
- 230000014509 gene expression Effects 0.000 claims description 46
- 210000001161 mammalian embryo Anatomy 0.000 claims description 28
- 239000013598 vector Substances 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 19
- 108020004999 messenger RNA Proteins 0.000 claims description 16
- 230000001404 mediated effect Effects 0.000 claims description 12
- 241000700605 Viruses Species 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 241001529936 Murinae Species 0.000 claims description 6
- 241000283984 Rodentia Species 0.000 claims description 6
- 238000010354 CRISPR gene editing Methods 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 238000002347 injection Methods 0.000 abstract description 31
- 239000007924 injection Substances 0.000 abstract description 31
- 238000012239 gene modification Methods 0.000 abstract description 24
- 230000005017 genetic modification Effects 0.000 abstract description 23
- 235000013617 genetically modified food Nutrition 0.000 abstract description 23
- 241000699670 Mus sp. Species 0.000 description 217
- 210000004027 cell Anatomy 0.000 description 165
- 230000035772 mutation Effects 0.000 description 42
- 238000010276 construction Methods 0.000 description 41
- 238000012163 sequencing technique Methods 0.000 description 40
- 108020004414 DNA Proteins 0.000 description 30
- 241000699666 Mus <mouse, genus> Species 0.000 description 25
- 230000011987 methylation Effects 0.000 description 23
- 238000007069 methylation reaction Methods 0.000 description 23
- 210000003783 haploid cell Anatomy 0.000 description 22
- 238000004458 analytical method Methods 0.000 description 19
- 238000003205 genotyping method Methods 0.000 description 19
- 239000002609 medium Substances 0.000 description 16
- 102100027881 Tumor protein 63 Human genes 0.000 description 15
- 238000001514 detection method Methods 0.000 description 15
- 230000018109 developmental process Effects 0.000 description 15
- 238000012217 deletion Methods 0.000 description 14
- 230000037430 deletion Effects 0.000 description 14
- 238000011161 development Methods 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 12
- 101150002416 Igf2 gene Proteins 0.000 description 12
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 11
- 238000010367 cloning Methods 0.000 description 11
- 230000004048 modification Effects 0.000 description 11
- 238000012986 modification Methods 0.000 description 11
- 102000018252 Tumor Protein p73 Human genes 0.000 description 10
- 210000000349 chromosome Anatomy 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 238000003780 insertion Methods 0.000 description 10
- 230000037431 insertion Effects 0.000 description 10
- 230000008775 paternal effect Effects 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- 238000012216 screening Methods 0.000 description 10
- 108091005942 ECFP Proteins 0.000 description 9
- 230000001413 cellular effect Effects 0.000 description 9
- 101150102995 dlk-1 gene Proteins 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 230000002159 abnormal effect Effects 0.000 description 8
- 238000010362 genome editing Methods 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 108700028369 Alleles Proteins 0.000 description 7
- 206010064571 Gene mutation Diseases 0.000 description 7
- 238000003559 RNA-seq method Methods 0.000 description 7
- 210000002459 blastocyst Anatomy 0.000 description 7
- 210000002304 esc Anatomy 0.000 description 7
- 230000008774 maternal effect Effects 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 238000011144 upstream manufacturing Methods 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 238000010448 genetic screening Methods 0.000 description 6
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 6
- 238000003753 real-time PCR Methods 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 238000011740 C57BL/6 mouse Methods 0.000 description 4
- 102000016897 CCCTC-Binding Factor Human genes 0.000 description 4
- 108010014064 CCCTC-Binding Factor Proteins 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N Glutamine Chemical compound OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- 101000653374 Homo sapiens Methylcytosine dioxygenase TET2 Proteins 0.000 description 4
- 101000653369 Homo sapiens Methylcytosine dioxygenase TET3 Proteins 0.000 description 4
- 102100030803 Methylcytosine dioxygenase TET2 Human genes 0.000 description 4
- 102100030812 Methylcytosine dioxygenase TET3 Human genes 0.000 description 4
- 101100388055 Mus musculus Polm gene Proteins 0.000 description 4
- 101150063416 add gene Proteins 0.000 description 4
- 238000010195 expression analysis Methods 0.000 description 4
- 238000003209 gene knockout Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 102000041788 p53 family Human genes 0.000 description 4
- 108091075611 p53 family Proteins 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000010453 CRISPR/Cas method Methods 0.000 description 3
- 230000007067 DNA methylation Effects 0.000 description 3
- 101000653360 Homo sapiens Methylcytosine dioxygenase TET1 Proteins 0.000 description 3
- 102100030819 Methylcytosine dioxygenase TET1 Human genes 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 238000001369 bisulfite sequencing Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 101150024031 dio3 gene Proteins 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000030279 gene silencing Effects 0.000 description 3
- 230000009368 gene silencing by RNA Effects 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000012212 insulator Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 229950010131 puromycin Drugs 0.000 description 3
- 125000006853 reporter group Chemical group 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 description 2
- 206010068051 Chimerism Diseases 0.000 description 2
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 2
- 239000012097 Lipofectamine 2000 Substances 0.000 description 2
- 241000244206 Nematoda Species 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- 238000001190 Q-PCR Methods 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 241000270295 Serpentes Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000035199 Tetraploidy Diseases 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 2
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 238000003198 gene knock in Methods 0.000 description 2
- 238000012252 genetic analysis Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 238000012164 methylation sequencing Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 101150028074 2 gene Proteins 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- 101150090724 3 gene Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 101100447432 Danio rerio gapdh-2 gene Proteins 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 101000631705 Homo sapiens Signal peptide, CUB and EGF-like domain-containing protein 1 Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102100028926 Signal peptide, CUB and EGF-like domain-containing protein 1 Human genes 0.000 description 1
- 102000043123 TET family Human genes 0.000 description 1
- 108091084976 TET family Proteins 0.000 description 1
- 101150059786 Tet1 gene Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229930189065 blasticidin Natural products 0.000 description 1
- 210000000625 blastula Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012350 deep sequencing Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000007159 enucleation Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 230000006565 epigenetic process Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- -1 mCherry Proteins 0.000 description 1
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 210000000472 morula Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001776 parthenogenetic effect Effects 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
- C12N15/877—Techniques for producing new mammalian cloned embryos
- C12N15/8775—Murine embryos
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/50—Soluble polymers, e.g. polyethyleneglycol [PEG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/065—Modulators of histone acetylation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/235—Leukemia inhibitory factor [LIF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases [EC 2.]
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Definitions
- the present invention relates to biotechnologies, and specifically to an androgenetic haploid embryonic stem cell (AG-haESC), and a preparation method and use thereof.
- AG-haESC an androgenetic haploid embryonic stem cell
- RNA interference RNA interference
- haploid embryonic stem cells (haESCs) (Elling, U., Taubenschmid, J., Wirnsberger, G., O'Malley, R., Demers, S. P., Vanhaelen, Q., Shukalyuk, A. I., Schmauss, G., Schramek, D., Schnuetgen, F., et al. (2011). Forward and reverse genetics through derivation of haploid mouse embryonic stem cells. Cell Stem Cell 9, 563-574; and Leeb, M., and Wutz, A. (2011). Derivation of haploid embryonic stem cells from mouse embryos. Nature 479, 131-134) provides a desirable tool for genetic analysis.
- haESCs mammalian haploid embryonic stem cells
- AG-haESCs The androgenetic haploid embryonic stem cells
- ICAHCI intracytoplasmic AG-haESCs injection
- semi-cloned animal a viable animal subject that is referred to as semi-cloned animal. It is inferred that if semi-cloned mice can be produced with AG-haESCs efficiently and stably by ICAHCI, important genes involved in a particular developmental process can be screened out by using AG-haESCs as fertilizing vectors to carry genome-wide CRISPR-Cas9 knockout library.
- imprinted genes that are expressed in a parent-of-origin-specific manner are considered as an important barrier to the development of uniparental embryos, so that the normal growth and development of embryos require both the maternal and paternal genomes.
- DMRs differentially methylated regions
- DMR differentially methylated region
- the maternally expressed H19 gene is adjacent to the paternally expressed Igf2, and both of them are regulated by the same DMR.
- This DMR is amenable to DNA methylation in the paternal allele, and as a CTCF-dependent insulator, permits the expression of the maternal allele only.
- the methylation state of this DMR determines whether H19 (where H19 is expressed, DMR is demethylated, and the insulator is activated) or Igf2 (where Igf2 is expressed, DMR is methylated, and the insulator is deactivated) is expressed.
- knockout of the H19 gene or its DMR does not lead to any severe phenotype in mice (Leighton, P. A., Ingram, R.
- an object of the present invention is to provide an androgenetic haploid embryonic stem cell (AG-haESC) that can enhance the birth rate of semi-cloned animals and use thereof.
- AG-haESC androgenetic haploid embryonic stem cell
- the most possible cause of low birth rate is the occurrence of abnormal imprinting status of the androgenetic haploid. It is surprisingly found through experiments that characteristics of the AG-haESCs resembling those of a round spermatid can be established by knocking out the differentially methylated regions (DMRs) of two imprinted clusters H19-Igf2 and Dlk1-Dio3. Such AG-haESCs with two DMRs knocked out is designated as DKO-AG-haESCs.
- DMRs differentially methylated regions
- DKO-AG-haESCs With the DKO-AG-haESCs, semi-cloned mice can be obtained effectively (with a birth rate of SC mice of about 20%), and semi-cloned animals with multiple genetic modifications can still be produced stably after in-vitro genetic manipulation of the AG-haESCs. Unexpectedly, a large number of mutant animals can be effectively obtained in one step simply by transfecting the DKO-AG-haESCs with stable expression of sgRNA library and Cas9 in vitro at the cellular level. These experimental results show that DKO-AG-haESCs can be used as an intermediate to achieve gene mutation at the individual level by carrying the sgRNA library and therefore can be further used in gene mutation-based large-scale screening at individual animal level.
- a first aspect of the present invention provides an AG-haESC, in which H19 DMR and IG-DMR genes are knocked out.
- a second aspect of the present invention provides a method for preparing the AG-haESC, which comprises knocking out H19 DMR and IG-DMR from an AG-haESC, to obtain the above mentioned AG-haESC.
- a third aspect of the present invention provides use of the AG-haESC in constructing a genetically modified semi-cloned animal.
- a fourth aspect of the present invention provides a method for constructing a genetically modified semi-cloned animal, which comprises combining an AG-haESC in which H19 DMR and IG-DMR genes are both knocked out with an oocyte to obtain a semi-cloned embryo, and incubating the semi-cloned embryo, to obtain a semi-cloned animal.
- a fifth aspect of the present invention provides a genetically modified animal, which is constructed according to the above method, or is a sexually reproduced offspring of a semi-cloned animal constructed according to the above method.
- a sixth aspect of the present invention provides a method for constructing a genetically modified semi-cloned animal library with the AG-haESCs according to the present invention and a lentiviral sgRNA library.
- a seventh aspect of the present invention provides a genetically modified semi-cloned animal library constructed by using the above method.
- the present invention has the following beneficial effects.
- DKO-AG-haESCs can be effectively used for multi-gene genetic manipulation, and SC mice with multiple genetic modifications can be further obtained by ICAHCI. More importantly, by incorporating with a sgRNA library, DKO-AG-haESCs can be effectively used in one-step generation of heterozygous and homozygous mutant mice, providing further evidence for gene knockout-based screening at animal individual level.
- DKO-AG-haESCs-mediated gene editing technology provides a unique set of system for well phenotyping and screening genetically modified DKO-AG-haESCs, to ensure that the resulting SC animals exhibit the expected genetic traits, so the occurrence of chimerism can be largely avoided.
- genetically modified mice obtained by conventionally injecting diploid embryonic stem cells into the blastocysts need to experience the germline transmission of chimeric mice.
- the step of germline transmission is often very time-consuming. More seriously, the diploid embryonic stem cells with multiple genetic modifications may exhibit trait segregation in their offspring during germline transmission. Only a small percentage of offspring may contain all the desired genetic modifications.
- F0 mice with multiple genetic modifications can be obtained with DKO-AG-haESCs in one step.
- fully ESC-derived mice can be obtained in one step by injecting diploid embryonic stem cells into the tetraploid blastocysts (also known as tetraploid complementation technique). This method is also widely used and is the most stringent standard for testing the pluripotency of reprogrammed cells such as induced pluripotent stem cells (iPSCs) and nuclear transfer embryonic stem cells (ntESCs).
- iPSCs induced pluripotent stem cells
- ntESCs nuclear transfer embryonic stem cells
- the birth rate of the embryonic stem cell (ESC)- or iPSC-derived animals is very low, probably due to the epigenetic instability of diploid embryonic stem cells.
- ICAHCI a sophiscated technology for various mammals, including non-human primates and human. Cynomolgus monkey-derived haploid embryonic stem cell line has now been successfully established and the ICAHCI technology may be used in the near future to efficiently and rapidly obtain genetically modified non-human primates. Lastly, a large number of genetically mutated animals can be obtained with DKO-AG-haESCs by incorporating with a sgRNA library.
- this method is simpler and less labor-intensive than direct injection of plasmids or mRNAs into embryos for the large-scale production of mutant animals, since the DKO-AG-haESC line, which carries constantly expressed Cas9 and sgRNA library, can repeatedly serve as a donor for injection, to produce various genetically mutated animals continuously and effectively.
- These various mutant animals can be easily and quickly identified for the sgRNA insertion (which is exactly a barcode for a mutant animal) by PCR using a universal pair of primers.
- the method of injecting plasmids or mRNAs directly into embryos requires separate preparation of sgRNAs for each individual injection.
- the mutant animals obtained need to be housed separately, and the subsequent identification requires the use of corresponding primers for a particular gene. It is conceivable that some of the differentially expressed genes obtained from an appropriate sgRNA library, such as those obtained by high-throughput analysis at the cellular level, can be classified into a sub-library of sgRNAs that may be involved in a particular stage of development. By using the DKO-AG-haESC solution, important genes related to this development process can be rapidly and effectively screened out at the individual level.
- FIG. 1A is a view schematically showing the production of SC mice by intracytoplasmic AG-haESCs injection (ICAHCI) of AG-haESCs bearing 2 DMR knockouts.
- ICAHCI intracytoplasmic AG-haESCs injection
- FIG. 1B shows androgenetic haploid embryos produced by injection of H19 ⁇ DMR spermatids into enucleated MII oocytes.
- FIG. 1C shows one of the AG-haESC lines established with an androgenetic haploid blastocyst.
- FIG. 1D shows H19 ⁇ DMR AG-haESCs (H19 ⁇ DMR -AGH-1) established by multiple FACS enrichments of haploid cells.
- FIG. 1E shows SC mice produced with H19 ⁇ DMR -AGH-1 (p8) by ICAHCI.
- FIG. 1F is a view schematically showing an IG-DMR knockout sgRNA sequence.
- FIG. 1G shows production of H19 ⁇ DMR -IG ⁇ DMR -AGH-1 cell line.
- Left panel collected mCherry positive cells plated in a Petri dish.
- Right panel established H19 ⁇ DMR -IG ⁇ DMR -AGH cell line (H19 ⁇ DMR -IG ⁇ DMR -AGH-4).
- FIG. 1H shows SC mice produced with H19 ⁇ DMR -IG ⁇ DMR -AGU-4 (p29) by ICAHCI.
- Fig. S 1 A shows genotyping of H19 ⁇ DMR -AGH cell line.
- Fig. S 1 B shows that 80% of the embryos reconstructed with H19 ⁇ DMR -AGH cells reach 2-cell embryos, which is similar to the developmental rate obtained upon round spermatid injection (ROSI).
- Fig. S 1 C shows SC mice produced with H19 ⁇ DMR -AGH-1, 2, 3 cell lines by ICAHCI, in which asterisk represents growth-arrested SC mice.
- Fig. S 1 D shows genotyping of H19 ⁇ DMR -AGH cell-derived SC mice.
- Fig. S 1 E shows expression analysis of imprinted gene (Gtl2 and Dlk1) in various organs of H19 ⁇ DMR -AGH cell-derived normal and growth-arrested SC mice.
- Fig. S 1 F shows severely erased methylation imprinting of IG-DMR in growth-arrested SC mice.
- Fig. S 1 G shows Cobra assay of IG-DMR in growth-arrested and normal SC mice.
- Fig. S 1 H shows methylation state of IG-DMR in H19 ⁇ DMR -AGH cell line.
- FIG. 2A shows semi-cloned mice produced with IG ⁇ DMR -AGH-1 cell line (P17), in which asterisk represents growth-arrested SC mice, which die shortly after birth.
- FIG. 2B shows methylation state of H19 DMR in normal and abnormal SC mice produced with IG ⁇ DMR -AGR-1 cell line.
- FIG. 2C schematically shows H19 DMR knockout sgRNAs designed.
- FIG. 2D shows genotyping of H19 ⁇ DMR -IG ⁇ DMR -AGH-OG3 cell lines, produced by knocking out H19 and IG-DMRs from AGH-OG3 cell line.
- FIG. 2E shows genotyping of offspring obtained by mating SC mice produced with DKO-AG-haESCs, where the offspring carrying IG-DMR die before or shortly after birth.
- FIG. 2F shows analysis of gene expression profile of DKO-AG-haESCs by RNA-seq.
- the gene expression profile is clustering of the expression of all genes.
- the three DKO-AG-haESC cell lines show a gene expression profile that is similar to that of the AG-haESCs in the control group, but very different from that of the round spermatid.
- G0/G1 cells are collected by FACS for RNA-seq.
- FIG. 2G shows imprinted gene expression profile of DKO-AG-haESCs.
- the expression profiles of three different DKO-AG-haESC lines are similar to that of the AG-haESCs in the control group, but different from that of the round spermatids in mice
- FIG. 2H shows analysis of methylation in DKO-AG-haESCs by RRBS.
- Fig. S 2 A shows genotyping of H19 ⁇ DMR -IG ⁇ DMR -AGH cell line obtained by knocking out IG-DMR from H19 ⁇ DMR -AGH cells.
- Fig. S 2 B shows the sequencing result of a DKO-AG-haESC cell line (H19 ⁇ DMR -IG ⁇ DMR -AGH-4).
- Fig. S 2 C shows 2-cell embryos obtained with H19 ⁇ DMR -IG ⁇ DMR -AGR cells by ICAHCI.
- Fig. S 2 D shows genotyping of SC mice, where H19 ⁇ DMR -IG ⁇ DMR -AGH-4-derived SC mice all have H19 and IG DMR knockouts.
- Fig. S 2 E shows SC mice produced with IG ⁇ DMR -AGH-2 (p8).
- Fig. S 2 F shows the methylation state of H19 DMR in IG ⁇ DMR -AGH cells.
- Fig. S 2 G shows the methylation state of H19 DM in IG ⁇ DMR -AGH-2-derived normal and growth-arrested SC mice.
- Fig. S 2 H shows sequencing of a DKO-AG-haESC cell line (IG ⁇ DMR -H19 ⁇ DMR -AGH-2).
- Fig. S 2 I shows SC mice produced with IG ⁇ DMR H19 ⁇ DMR -AGH-2 cells (p24) by ICAHCI.
- FIG. 52J shows genotyping of IG ⁇ DMR -H19 ⁇ DMR -AGR-2-derived SC mice.
- FIG. 3A is a view schematically showing Tet1, Tet2 and Tet3 sgRNAs.
- FIG. 3B shows mCherry positive cells collected by FACS, which are plated in a Petri dish, to obtain DKO-AG-haESCs with mutant Tet family of genes.
- FIG. 3C shows a Tet-TKO-DAH cell line obtained.
- FIG. 3D shows sequencing of Tet1, Tet2 and Tet3 in the Tet-TKO-DAH cell line.
- FIG. 3E shows sequencing of PCR products of Tet1, Tet2 and Tet3 genes in SC mice produced with Tet-TKO-DAH-1 and Tet-TKO-DAH-2 cell lines.
- FIG. 3F is a view schematically showing p53, p63 and p73 sgRNAs.
- FIG. 3G shows sequencing of p53, p63 and p73 in p53-TKO-DAH-2 cell line.
- FIG. 3H is a view schematically showing Tet1-EGFP, Tet2-mCherry, and Tet1-ECFP double-stranded DNA vectors, in which EGFP, mCherry, and ECFP are respectively fused to a stop codon of Tet1, Tet2, and Tet3.
- FIG. 3I shows genotyping of Tet-TKO-DAH-1 cell line.
- Fig. S 3 A shows sequencing of 2 DKO-AG-haESCs cell lines (H19 ⁇ DMR -IG ⁇ DMR -AGH-OG3-1 and H19 ⁇ DMR -IG ⁇ DMR -AGH-OG3-1) obtained by knocking out H19 and IG-DMR from WT-AG-haESCs (AGH-OG3).
- Fig. S 3 B shows SC mice produced with H19 ⁇ DMR -IG ⁇ DMR -AGU-OG3-1 (p26) by ICAHCI.
- Fig. S 3 C shows genotyping of SC mice produced with H19 ⁇ DMR -IG ⁇ DMR -AGH-OG3-2 cell line.
- Fig. S 3 D shows expression analysis of imprinted gene (H19, Igf2, Gtl2 and Dlk1) in DKO-AG-haESCs and normal AG-haESCs, where after H19 and IG-DMR are knocked out, the expression of H19 and Gtl2 in AGH-OG-3 is down regulated, while the expression of Igf2 and Dlk1 is up regulated.
- imprinted gene H19, Igf2, Gtl2 and Dlk1
- Fig. S 3 E shows bigwig track of H19 and Gtl2.
- the RNA-seq result shows that compared with WT-AG-haESCs, the expression level of H19 and Gtl2 in DKO-AG-haESCs is much lower.
- Fig. S 3 F shows the methylation levels in H19-Igf2 and Dlk1-Dio3 imprinted cluster regions.
- Fig. S 3 G shows the methylation state of imprinted genes in DKO-AG-haESCs, WT-AG-haESCs, and round spermatids.
- FIG. 4A is a view schematically showing a large number of heterozygous mutant SC mice produced with DKO-AG-haESCs carrying sgRNA library by ICAHCI.
- FIG. 4B represents mCherry-positive haploid cells successfully transfected with Cas9 enriched by FACS for subsequent ICAHCI.
- FIG. 4C shows PCR identification of sgRNAs in single cell derived haploid clones, where the tested cell clones all carry sgRNAs.
- FIG. 4D shows sequencing of different mutant genes in cell clones, where the tested cell clones all have modifications of the genes of interest.
- FIG. 4E shows SC mice derived from DKO-AG-haESCs carrying sgRNA library.
- FIG. 4F shows PCR identification of sgRNAs in SC mice.
- FIG. 4G shows sequencing of different mutant genes of interest in SC mice, where all the tested SC mice have modifications of the genes of interest.
- Fig. S 4 A shows sequencing of Tet1, Tet2 and Tet3 in Tet-TKO-DAH-3 cell line.
- Fig. S 4 B shows SC mice produced with Tet-TKO-DAH-3 (p36) by ICAHCI.
- Fig. S 4 C shows sequencing of p53, p63 and p73 in p53-TKO-DAH-1 cell line.
- Fig. S 4 D shows SC mice produced with p53-TKO-DAH-1 cell line (p44) by ICAHCI.
- Fig. S 4 E shows sequencing of p53, p63 and p73 in SC mice produced with p53-TKO-DAH-1 and p53-TKO-DAH-2 cell line.
- FIG. 5A is schematic representation of a large number of bi-allelic mutant SC mice produced by ICAHCI with DKO-AG-haESCs that carry consistently expressed Cas9 and sgRNA library.
- FIG. 5B shows PCR analysis of Cas9 in single cell-derived cell clone, where all tested cell clones comprises the Cas9 transgene.
- FIG. 5C shows quantitative PCR analysis of Cas9 in single cell-derived cell clones.
- FIG. 5D shows PCR identification of sgRNAs in single cell-derived cell clones.
- FIG. 5E shows SC mice derived from DKO-AG-haESCs that carry constantly expressed Cas9 and sgRNA library.
- FIG. 5F shows PCR identification of sgRNAs in SC mice.
- FIG. 5G shows bi-allelic mutant SC mice produced by ICAHCI with DKO-AG-haESCs that carry constantly expressed Cas9 and sgRNA Library, in which the Polm bi-allelic mutant SC mice are taken as an example.
- FIG. 5H shows analysis of the polm gene mutation in the mouse tail by TA cloning and sequencing, where 24 out of 26 tested clones have a frameshift mutation.
- FIG. 5I shows summary of TA cloning and sequencing results of 7 bi-allelic mutant SC mice, in which more than 80% of the clones have insertion or deletion mutations.
- FIG. 5J shows TA cloning and sequencing of different organs in Scube1 bi-allelic mutant SC mice.
- Fig. S 5 A is a view schematically showing Tet1-EGFP, Tet2-mCherry, and Tet3-ECFP exogenous double-stranded vectors.
- Fig. S 5 B shows genotyping of Tet1-EGFP knock-in DKO-AG-haESCs.
- Fig. S 5 C shows genotyping of Tet3-ECFP knock-in DKO-AG-haESCs.
- Fig. S 5 D shows genotyping of Tet1&3-KI-DAH-1 cell line.
- Fig. S 5 E shows sequencing of Tet1-EGFP and Tet-ECFP in Tet1&3-KI-DAH-1 cell line.
- Fig. S 5 F shows 3-week-old SC mice produced with Tet1&3-KI-DAH-1 cell line (p40) by ICAHCI.
- Fig. S 5 G shows genotyping of SC mice produced with Tet1&3-KI-DAH-1 cell line.
- Fig. S 5 H shows sequencing of Tet2-mCherry in Tet-TKI-DAH-1 cell line.
- Fig. S 5 I shows SC mice produced with Tet-TKI-DAH-2 cell line (p50).
- Fig. S 5 J shows genotyping of SC mice produced with Tet-TKI-DAH-1 cell line.
- Fig. S 6 A shows bi-allelic mutant mice produced by injecting haploid cells transiently treansfected with pX330-mCheny plasmid and carrying sgRNAs into mature oocytes and then injecting Cas9 mRNA to the reconstructed oocytes (where the protocol is known as Lenti -sgRNA+pX330+Cas9 injection).
- Fig. S 6 B shows PCR identification of sgRNA insertion into single cell-derived haploid ES clones.
- Fig. S 6 C shows SC mice produced with DKO-AG-haESCs carrying sgRNA library.
- Fig. S 6 D shows PCR identification of sgRNAs in SC mice.
- Fig. S 6 E shows bi-allelic mutant mice produced by injecting DKO-AG-haESCs carrying sgRNA library into oocytes, and then injecting Cas9 mRNA to SC embryos, in which bi-allelic mutant mice carrying Slco5al gene are taken as an example.
- Fig. S 6 F shows TA cloning and sequencing of tails of mice carrying Slco5al gene, where 18 out of the 20 tested clones have insertion or deletion mutations.
- Fig. S 6 G shows summary of TA cloning and sequencing results of 4 bi-allelic mutant mice.
- the present invention provides an androgenetic haploid embryonic stem cell (AG-haESC), in which H19DMR and IG-DMR are knocked out.
- AG-haESC androgenetic haploid embryonic stem cell
- the AG-haESCs have a whole genome derived from spermatid, has the self-replication ability and pluripotency of stem cells, and can replace the spermatid to combine with oocytes to support the full development of embryos.
- H19 DMR refers to a differentially methylated region (DMR) within the H19-Igf2 imprinted cluster.
- the specific location and sequence of H19 DMR can be determined according to the existing methods such as methylation sequencing or homologous sequence analysis and prediction.
- Human H19DMR is known to be located in the 1p15.5 region of the chromosome 1 and the mouse H19 DMR is located at the distal end of chromosome 7 between the two genes H19 and Igf2, a position from 2 kb to 4 kb upstream of the H19 gene.
- H19 DMR is methylated on the paternal allele, resulting in the inability of CTCF protein to bind to this methylated region so that the enhancer downstream of H19 does not need to cross over the obstacle CTCF, thereby increasing the expression of upstream Igf2 and decreasing the H19 expression.
- H19 DMR is demethylated on the maternal allele, and the CTCF protein is able to bind to this unmethylated region, so the enhancer downstream of H19 can only increase the H19 expression, and cannot regulate the upstream Igf2. If the paternal H19 DMR is knocked out, the enhancer downstream of H19 can upregulate the expression of Igf2.
- H19 DMR is knocked out and the abnormal state in which H19 expression is up-regulated and the Igf2 expression is down-regulated is corrected.
- IG-DMR refers to a differentially methylated region (DMR) within the Dlk-Dio3 imprinted cluster.
- the specific location and sequence of IG DMR can be determined according to the existing methods such as methylation sequencing or homologous sequence analysis and prediction.
- the mouse IG-DMR is known to be located on the chromosome 12 in a 4.15 kb repeat between the genes Dlk1 and Gtl2 in the imprinted cluster, and the human IG-DMR is located on the chromosome 14 (14q32.2).
- IG-DMR is DNA methylated on the paternal allele, so the gene Gtl2 and some micromRNAs in this imprinted cluster are not expressed while the gene Rtl1, Dlk1 and Dio3 are expressed.
- IG-DMR is un-DNA methylated (in demethylated state) on the maternal allele, so Gtl2 and some micromRNAs are expressed while the gene Rtl1, Dlk1 and Dio3 are not expressed.
- AG-haESCs undergo other genetic modifications in addition to H19 DMR and IG-DMR knockouts.
- genetic modification refers to the structural change of a gene made by a biological, chemical or physical means compared with that before modification, and this change mainly refers to the change in base pair composition, comprising, but not limited to, changes caused by the replacement, insertion, and deletion of one or more base pairs.
- Tet1, Tet2, Tet3 and p53 family of genes are exemplified.
- the AG-haESCs are derived from mammals, comprising human or non-human mammals.
- the AG-haESCs are derived from a rodent, such as rabbit and murine that may be a mouse or a rat.
- the AG-haESCs are derived from mice.
- the birth rate of semi-cloned animals constructed with the AG-haESCs of the present invention is higher.
- the present invention also provides a method for preparing the AG-haESCs, which comprises knocking out the H19 DMR and IG-DMR from AG-haESCs, to obtain the AG-haESCs.
- the H19 DMR and IG-DMR can be knocked out by using an existing gene editing method.
- the H19 DMR and IG-DMR are knocked out using CRISPR/Cas9-mediated gene manipulation.
- Gene knockouts may also be performed by other methods, and the present invention is not limited to the methods listed in the examples.
- H19 DMR knockout Due to the H19 DMR knockout, the complete sequence of H19 DMR is removed from the chromosome DNA; and due to the IG DMR knockout, the complete sequence of IG-DMR is removed from the chromosome DNA.
- H19 DMR knockout AG-haESCs are constructed firstly, and then IG-DMR is further knocked out.
- IG-DMR knockout AG-haESCs are constructed firstly and then H19 DMR is further knocked out.
- AG-haESCs in which H19 DMR and IG-DMR are both knocked out are directly constructed.
- Such other genetic modifications refer to genetic modifications other than H19 DMR and IG-DMR knockouts.
- Such other genetic modifications may be the modification of a single target gene or the modifications of multiple target genes of interest.
- the target gene of interest is not specific and can be set and modified as desired in the research.
- such other genetic modifications may be the modifications of one, two or more target genes.
- the AG-haESCs of the present invention in which H19 DMR and IG-DMR are both knocked out can be passaged in vitro, and thus they can theoretically be genetically modified constantly.
- the number of modifications made to the target gene can be set as needed without particular limitation.
- the genetic modifications comprise, but are not limited to, knock-in and knock-out of a target gene, and the like.
- the knock-in and knock-out of a target gene may be accomplished by techniques such as gene targeting and homologous recombination, comprising, but not limited to, genetic manipulation based on ZFN (zinc finger nuclease), TALEN (transcriptional activator-like effector nuclease) and CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats).
- the AG-haESCs in which the H19 DMR and IG-DMR are both knocked out undergo one or more genetic modifications to obtain the AG-haESCs with H19 DMR and IG-DMR knockouts and with other genetic modifications.
- AG-haESCs can be genetically modified first, followed by knocking out H19DMR and IG-DMR from the genetically mutated AG-haESCs.
- other biotechnological means that can achieve the H19 DMR and IG-DMR knockouts and other genetic mutations can also be used to construct the AG-haESCs with H19 DMR and IG-DMR knockouts and with other genetic modifications.
- the present invention also provides the use of the AG-haESCs in constructing genetically modified semi-cloned animals. Further, the AG-haESCs are used as a fertilizing vector in place of spermatid in the construction of genetically modified animals.
- the present invention also provides a method for constructing a genetically modified semi-cloned animal, which comprises: combining an AG-haESC in which H19 DMR and IG-DMR are both knocked out with an oocyte to obtain a semi-cloned embryo, and incubating the semi-cloned embryo to obtain a semi-clone animal.
- the oocytes and the AG-haESCs are derived from the same kind of animal, preferably the same species of animal.
- the semi-cloned embryo may specifically be an semi-cloned embryo obtained by ICAHCI using the AG-haESCs in which H19 DMR and IG-DMR are both knocked out as a donor for ICAHCI.
- the semi-cloned animal can be obtained by incubating the semi-cloned embryo in a suitable female organism by embryo transfer.
- the suitable maternal is a pseudopregnant ICR female rat.
- the present invention further provides a genetically modified animal, which is constructed according to the above method, or is a sexually reproduced offspring of a semi-cloned animal constructed according to the above method.
- the semi-cloned animal according to the present invention may be a non-human mammal.
- the semi-cloned animal is a rodent, such as rabbit or murine.
- the semi-cloned animal is a mouse.
- the present invention also provides a method for constructing a genetically modified semi-cloned animal library, which comprises the steps of:
- the sgRNA lentiviral library plasmids comprise several lentiviral vectors that express different sgRNAs.
- the lentiviral sgRNA library can be constructed by current technologies, or existing lentiviral sgRNA library plasmids may be used. Specifically, sgRNAs designed for different genes can be cloned into lentiviral vectors. The sgRNA can be designed according to the gene of interest.
- a commercially available lentiviral sgRNA library of whole genomes of mice is employed.
- Step 2) may be selected from any one of:
- the AG-haESC library carrying the sgRNA library is further transfected with a plasmid expressing Cas9, and the semi-cloned embryos are obtained by ICAHCI using the resultant AG-haESCs as a donor for ICAHCI.
- AG-haESCs in the AG-haESC library carrying the sgRNA library, as a donor for ICAHCI are injected into mature oocytes by ICAHCI, and then Cas9 mRNA is injected into the reconstructed oocytes, to obtain the semi-cloned embryos.
- the AG-haESC library carrying the sgRNA library is further transfected with a plasmid expressing Cas9, the resultant AG-haESCs, as a donor for ICAHCI, are injected into mature oocytes by ICAHCI, and then Cas9 mRNA is injected into the reconstructed oocytes, to obtain the semi-cloned embryo, from which a semi-cloned animal is obtained after embryo transfer.
- the plasmid expressing Cas9 can be constructed by cloning the Cas9 expressing gene into an expression plasmid.
- the plasmid expressing Cas9 is pX330-mCherry plasmid.
- the plasmid that is constructed to express Cas9 is not limited to the pX330 plasmid.
- the expression plasmid only needs to be suitable for expression of exogenous genes in mammalian cells.
- the present invention further provides another method for constructing a genetically modified semi-cloned animal library, which comprises the steps of:
- the virus particles expressing Cas9 can be obtained by cloning the encoding gene expressing Cas9 into a lentiviral vector and then packaging the lentivirus in the prior art.
- the lentiviral vector expressing Cas9 is commercially available.
- the semi-cloned animal library comprises several genetically mutated semi-cloned animals.
- the animals may be heterozygous or biallelic mutant animals.
- semi-cloned animals can be obtained by culturing the semi-cloned embryos in a suitable female organism by embryo transfer.
- the suitable female organism may be a pseudopregnant ICR female rat.
- the present invention also provides a genetically modified semi-cloned animal library, which is constructed according to the method as described above.
- the genetically modified semi-cloned animal library of the present invention can be used in genetic screening of genes at subordinate individual level.
- the semi-cloned animal library of the present invention may be a non-human mammalian library.
- the semi-cloned animal library is a rodent library, such as a rabbit library, and a murine library.
- the semi-cloned animal library is a mouse library.
- AG-haESCs androgenetic haploid embryonic stem cells
- DKO-AG-haESCs H19 DMR and IG-DMR double knockout androgenetic haploid embryonic stem cell
- the cell culture medium (DMEM), fetal bovine serum (FBS), serum replacement (KSR), trypsin, Opti-MEM, DPBS, and Lipofectamine 2000 were purchased from Life Technologies Inc.; the restriction endonucleases and T4 ligase were purchased from NEB; the Taq enzyme and dNTPs were purchased from TaKaRa; the CDNA reverse transcription kit, and fluorescent quantification reagent SYBR-Green were purchased from TOYOBO; and the oligonucleotides were synthesized by Shanghai Generay Company.
- TSA Trichostatin A
- KSOM culture medium (KSOM+AA with glucose): millipore, CAT#MR-106-D
- DMEM millipore, CAT#SLM-220-M 75%, 20% serum replacement KSR (Gibco, CAT#10828-028), 1,500 U/ml LIF (Millopre, CAT#ESG1107), 3M CHIR99021 (Stemgent, CAT#04-0004), and 1M PD0325901 (Stemgent, CAT#04-0006)
- mCherry-F ATTTGCGGCCGCATAGTAATCAATTACGGG
- mCherry-R ATTTGCGGCCGCATGCAGTGAAAAAAATGC
- mice testis was digested with collagenase IV for 20 minutes and then with trypsin for 10 minutes, and then sorted by FACS, to obtain round spermatid of mice.
- H19 ⁇ 3.8 kb KO mice (C57/B6 background, homozygous): constructed as described in (Thorvaldsen, J. L., Mann, M R., Nwoko, O., Duran, K. L., and Bartolomei, M. S. (2002). Analysis of sequence upstream of the endogenous H19 gene reveals elements both essential and dispensable for imprinting. Molecular and cellular biology 22, 2450-2462.)
- IG-DMRKO mice C57/B6 background, heterozygous: constructed as described in (Lin, S. P., Youngson, N., Takada, S., Seitz, H., Reik, W., Paulsen, M., Cavaille, J., and Ferguson-Smith, A C. (2003). Asymmetric regulation of imprinting on the maternal and paternal chromosomes at the Dlk1-Gtl2 imprinted cluster on mouse chromosome 12. Nature genetics 35, 97-102)
- B6D2F1 (C57BL/6 ⁇ DBA2) female mice: female offspring obtained after mating with female mice of C57BL/6 strain with male mice of DBA2 strain.
- ICR adult female mice purchased from SLAC Laboratory Animal Co., Ltd were mated with ligated adult ICR male mice, to obtain pseudopregnant ICR female rats.
- the AG-haESC line was constructed according a reported method (Yang, H., Shi, L., Wang, B. A., Liang, D., Zhong, C., Liu, W., Nie, Y., Liu, J., Zhao, J., Gao, X., et al. (2012). Generation of genetically modified mice by oocyte injection of androgenetic haploid embryonic stem cells. Cell 149, 605-617).
- the MII oocytes were enucleated, into which the corresponding sperm heads were injected.
- Mouse MII oocytes were harvested 14 hours after treatment with human chorionic gonadotropin (HCG) and then enucleated using a Piezo needle in HEPES-CZB medium containing 5 ⁇ g/ml cytochalasin B (CB). After enucleation, single sperm heads were injected into the cytoplasm of the oocytes. The reconstructed embryos were cultured in CZB medium for 1 hour and then transferred to the activation solution containing 1 mM Sr 2+ for activation.
- HCG human chorionic gonadotropin
- CB cytochalasin B
- the zona pellucid of the reconstructed embryos was removed by digestion with the acid Tyrode solution.
- Each embryo was transferred to a 96-well plate plated with a mouse fibroblast feeder layer and cultured with ESC medium containing 20% serum replacement (KSR), 1,500 U/ml LIF, 3M CHIR99021 and 1 M PD0325901.
- KSR serum replacement
- the cell clones were trypsinized and transferred to a 96-well plate plated with a fresh feeder layer.
- the cells were further expanded, and passaged into a 48-well plate and further into a 6-well plate, and the cells were daily maintained in a 6-well plate.
- haploid cells After the embryonic stem cells were trypsinized, they were washed once with PBS (GIBCO) and then in ESC medium containing 15 ⁇ g/ml Hoechst 33342. After being placed in a water bath for 30 min, haploid cells of 1N peak were sorted by the flow cytometer BD FACS Ariall and subsequently subcultured to obtain the AG-haESC line.
- CRISPR-Cas9 plasmid The synthesized forward oligonucleotide strand and reverse oligonucleotide strand of sgRNA were annealed to obtain a double-stranded oligonucleotide strand (in the present invention, the sgRNA sequence refers to the sequence of the forward oligonucleotide strand of the sgRNA), which was then ligated to pX330-mCherry enzymatically cleaved with BbsI (New England Biolabs). The constructed corresponding plasmid was transfected into the AG-haESCs using Lipofectamine 2000 (Life Technologies) according to the instructions.
- haploid cells with the red fluorescent protein were sorted by flow cytometry (FACSAriaII, BD Biosciences) and then plated at a low density. After 4-5 days of growth, monoclones were picked up for subsequent construction of cell lineages. Finally, cell lines with corresponding gene mutations were obtained by sequencing target genes by PCR.
- a sequence encoding EGFP, mCherry or ECFP was amplified and then ligated to the pMD19-T vector, to give pMD19-T-EGFP/mCherry/ECFP. Subsequently, the left and right homologous arms of the target gene were inserted into the pMD 19-T-EGFP/mCherry/ECFP vector.
- mice The viral sgRNA library of mice and the Cas9 expressing viral plasmid have been reported mice (Cong., L, Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L A., et al. (2013). Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823; and Koike-Yusa, H., Li, Y., Tan, E. P., Velasco-Herrera Mdel, C., and Yusa, K. (2014).
- the viral sgRNA library of mice and the Cas9 expressing viral plasmid used in the present invention were provided by Addgene.
- HEK293T was passaged in advance into a 10 cm petri dish, 3 ⁇ g of viral plasmid (lentiviral sgRNA library or lentiviral Cas9) and 9 ⁇ g of ViraPower Lentiviral Packaging Mix (Invitrogen) were transfected into HEK293T cells by using Lipofectamine® 2000 Reagent (Invitrogen, Life Technologies). The supernatant were collected 72 hours after transfection and concentrated with Lenti -Concentin virus precipitation solution (SBI) and then stored at ⁇ 80° C.
- SBI Lenti -Concentin virus precipitation solution
- Infection with lentiviral Cas9 A cell suspension of 10 8 DKO-AG-haESCs was infected for 48 hours with 8 ⁇ g/ml polybrene (Sigma) and packaged lentiviral Cas9, and then screened for 3 days with 10 ⁇ g/ml blasticidin (Sigma). The remaining resistant clone was a cell line integrated with lentiviral Cas9.
- Infection with lentiviral sgRNA library A cell suspension of 10 8 DKO-AG-haESCs was infected for 48 hrs with 8 ⁇ g/ml polybrene (Sigma) and packaged lentiviral CRISPR-sgRNA library, and then screened for 2 days in a medium comprising 1 ⁇ g/ml puromycin (Invitrogen), to obtain a positive clone that is a cell line carrying lentiviral sgRNA library.
- a cell line integrated with lentiviral Cas9 was prepared first, then further infected with the lentiviral sgRNA library, and then screened for 2 days in a medium comprising 1 ⁇ g/ml puromycin (Invitrogen), to obtain a positive clone that is a cell line integrated with lentiviral Cas9 and lentiviral sgRNA library.
- the DKO-AG-haESC cell line was only infected with the lentiviral sgRNA library, then the cells did not express Cas9. At this time, transfection with the pX330-mCherry plasmid at the cellular level was needed to achieve the genome editing.
- Mouse DNA was packaged into beads with 15 ⁇ l of 2% LMP agarose (low melting point agarose), 460 ⁇ l of DNA digestion buffer, and then 40 ⁇ l of proteinase K were added to each sample and the sample was digested by incubation overnight at 50° C.
- LMP agarose low melting point agarose
- Nested PCR was performed using the beads as a template, and the PCR product was recovered and then ligated to the PMD19-T vector, followed by transformation and plating.
- EZ DNA methylation Gold kit ZYMO Research
- an appropriate amount of DNA was prepared, and the following procedures were operated according to the steps of use of the kit.
- the resulting product recovered with the kit was used as a template for PCR, the product was recovered and then ligated to the PMD19-T vector, followed by transformation and plating. 10 colonies were picked from the plate for sequencing.
- TOYOBO First Strand cDNA Synthesis kit
- Real-time fluorescent quantitative PCR reactions were performed on a Bio-Rad CFX96 instrument using SYBR Green Realtime PCR Master Mix (TOYOBO), with 3 replicates for each set of samples. All the gene expression levels were detected with the expression level of housekeeping gene Gapdh as an internal reference.
- Intracytoplasmic AG-haESCs injection ICAHCI
- AG-haESCs were treated for 8 hrs with a medium containing 0.05 ⁇ g/ml colchicine to synchronize the cells to M phase and then intracytoplasmically injected into the oocytes.
- the digested AG-haESCs were washed 3 times with HEPES-CZB medium and then re-suspended in 3% (w/v) polyvinylpyrrolidone (PVP) in HEPES-CZB medium.
- PVP polyvinylpyrrolidone
- the reconstructed embryos were cultured in CZB medium for 1 hour and then activated with a CB-free medium for 5-6 hours. After activation, all the reconstructed embryos were cultured in KSOM medium at 37° C., and 5% CO 2 . ICAHCI embryos reached 2-cell embryo after being cultured in the KSOM medium for 24 hours.
- ROSI round spermatid injection
- RNA-seq library of total RNA was established according to Illumina's official TreSeq RNA Sample Prep v2 Guide. After establishment, deep sequencing was performed on the IlluminaHiSeq 2000 instrument available from the Computational Biology Center of the Institute of Computing Biology, Chinese Academy of Sciences-Max-Planck-Gesellschaft zur touch dermaschineen e.V. 6 samples, comprising 2 WT AG-haESCs, H19 ⁇ DMR -IG ⁇ DMR -AGH, H19 ⁇ DMR -IG ⁇ DMR -AGH-OG3, IG ⁇ DMR -H19 ⁇ DMR -AGH and round spermatid were subjected to subsequent analysis.
- the algorithm for gene expression level was RPKM, specifically as described in (Yang, L., Duff, M. O., Graveley, B. R., Carmichael, G. G., and Chen, L. L. (2011). Genomewide characterization of non-polyadenylated RNAs. Genome biology 12, R16).
- the p-value of differentially expressed genes was calculated using the waldscore method (Yang et al., Genome boil 2011) in which abs (waldscore) was set to be >1.96 (that is, p-value ⁇ 0.05), and then the differentially expressed genes were screened.
- the RRBS library was established according to Illumina's official protocol, and then sequenced on the IlluminaHiSeq 2000 instrument (Gu, H., Smith, Z. D., Bock, C., Boyle, P., Gnirke, A., and Meissner, A. (2011). Preparation of reduced representation bisulfite sequencing libraries for genome-scale DNA methylation profiling. Nature protocols 6, 468-481.). All sequencing reads were aligned with the mouse genome.
- the extracted genomic DNA was amplified by PCR using corresponding primers, and the PCR product was further subjected to agarose gel electrophoresis.
- the haploid sperm heads of H19 ⁇ 3.8 kb mice were injected into enucleated oocytes ( FIG. 1A ) following the method as described in Section 1.3, to obtain reconstructed blastocysts, with which AG-haESC cell lines were constructed.
- Three haploid cell lines were established from 250 reconstructed blastocysts (which were designated as H19 ⁇ DMR -AGH-1, H19 ⁇ DMR -AGU-2, H19 ⁇ DMR -AGU-3) ( FIGS. 1B-1D ).
- H19-AGH cells were used as a donor for ICAHCI, and 1443 2-cell embryos reconstructed with these 3 cell lines were transferred into the pseudopregnant female mice.
- 86 healthy, viable semi-cloned mice and 39 growth-arrested mice were obtained by caesarean section of the female mice on day 19.5 after pregnancy ( FIG. 1E , Table 1).
- the birth rate in normal half-cloned mice is about 5.9%; however, about 2.7% of the semi-cloned mice developed from the embryos constructed with H19 ⁇ DMR -AGH still have abnormal growth.
- Semi-cloned mice were constructed with wild-type AG-haESCs as a donor for ICAHCI.
- the birth rate of normal semi-cloned mice is about 0.7-1.8%.
- Fluorescent quantitative PCR was used to detect whether aberrant high expression of Gtl2 was also present in the major organs of H19 ⁇ DMR -AGH-derived growth-arrested mice, following the method as described in Section 1.7.
- IG DMR-BS-OF TTAAGGTATTTTTTATTGATAAAATAATGTAGTTT IGD
- MR-BS-OR CCTACTCTATAATACCCTATATAATTATACCATAA
- IG DMR-BS-IF TTAGGAGTTAAGGAAAAGAAAGAAATAGTATAGT
- IG DMR-BS-IR TATACACAAAAATATATCTATATAACACCATACAA
- sgRNAs were designed according to the sequence between Dlk1 and Gtl2 which had a 4.15 kb IG-DMR knocked out (designated as IG-DMR-sgRNA1 and IG-DMR-sgRNA2) ( FIG. 1F ).
- IG-DMR-sgRNA1 sequence (SEQ ID NO: 1)
- IG-DMR-sgRNA2 sequence (SEQ ID NO: 2) CTGCTTAGAGGTACTACGCT
- the plasmids pX330-mCherry expressing Cas9 and IG-DMR-sgRNAs were constructed and transfected into the H19 ⁇ DMR -AGH cells, to finally obtain 71 AG-haESC lines.
- the sequencing of the PCR product of the target gene (IG-DMR deletion check-F: TGTGCAGCAGCAAAGCTAAG; IG-DMR deletion check-R: ATACGATACGGCAACCAACG) found that the IG-DMR were successfully knocked out in 58 cell lines (designated as H19 ⁇ DMR -IG ⁇ DMR -AGH-1 through H19 ⁇ DMR -IG ⁇ DMR -AGH-58) ( FIGS.
- the haploid sperm heads of IG-DMR KO mice were injected into enucleated oocytes following the method as described in Section 1.3, to obtain reconstructed blastocysts, with which AG-haESC cell lines were constructed.
- 2 cell lines carried IG-DMR knockout (designated as IG ⁇ DMR -AGH-1 and IG ⁇ DMR -AGH-2)
- IG ⁇ DMR -AGH cells were used as a donor for ICAHC to construct semi-cloned mice. It is found that the IG ⁇ DMR -AGH cells are not donors effective in the production of semi-cloned mice (Table 1, Table S1), with which it is difficult to obtain healthy normal SC mice (where only 4 normal SC mice are obtained from 499 transferred embryos) ( FIGS. 2A and S 2 E). Moreover, most of the mice are growth arrested.
- H19 DMR-BS-OF 5′ GAGTATTTAGGAGGTATAAGAATT 3′
- H19 DMR-BS-OR 5′ ATCAAAAACTAACATAAACCCCT 3′
- H19 DMR-BS-IF 5′ GTAAGGAGATTATGTTTATTTTTGG 3′
- H19 DMR-BS-IR 5′ CCTCATTAATCCCATAACTAT 3′
- H19 ⁇ 3.8kb DMR KO sgRNA sequence H19-3.8K sgRNA-1: (SEQ ID NO: 3) CATGAACTCAGAAGAGACTG H19-3.8K sgRNA-2: (SEQ ID NO: 4) AGGTGAGAACCACTGCTGAG
- the H19 ⁇ 3.8 kb DMR were knocked out from the IG DMR -AGH cell line obtained in the above example by the CRISPR-Cas9 method (see Thorvaldsen, J. L., Mann, M. R., Nwoko, O., Duran, K. L., and Bartolomei, M. S. (2002).
- Analysis of sequence upstream of the endogenous H19 gene reveals elements both essential and dispensable for imprinting.
- the oligo of sgRNA were annealed and then the sgRNAs of H19 and IG-DMR were respectively ligated to the BbsI digested px330-mCherry plasmid and transformed. Plasmid was extracted from the bacterial suspension sequenced to be correct for subsequent transfection.
- the 21st generation of the AGH-OG-3 cell line was transformed with the plasmid obtained above.
- H19 ⁇ DMR -IG ⁇ DMR -AGH-OG3 cells were used as a donor for ICAHCI to construct semi-cloned mice.
- ICAHCI ICAHCI-associated embryos
- WT-AG-haESCs which had previously completely lost the ability to produce SC mice, were able to regain characteristics resembling a round spermatid after knockdown of H19-DMR and IG-DMR.
- Genotyping method The method as described in Section 1.12 was used.
- H19-DMR deletion check-F2 GTGGTTAGTTCTATATGGGG H19-DMR deletion check-R2: TCTTACAGTCTGGTCTTGGT IG-DMR deletion check-F: TGTGCAGCAGCAAAGCTAAG IG-DMR deletion check-R: ATACGATACGGCAACCAACG
- H19-DMR and IG-DMR double-knockout AG-haESC cell lines were constructed by using the three methods described in the foregoing Examples 2, 4 and 5, and a total of 402 SC mice were obtained. A mouse birth rate of 20.2% was achieved with the transferred embryos. These DKO-AG-haESC derived SC mice are able to grow to adulthood and are capable of producing offspring. Genotyping of 33 neonatal mouse offspring in 7 litters find that 13 animals carry H19-DMR knockout and 11 animals are WT ( FIG. 2E ). 6 out of the other 9 mice have IG-DMR knockout and 3 have H19 and Gtl2 DMR double knockouts.
- mice died shortly after birth, consistent with the previously reported lethal phenotype of the maternally inherited IG-DMR before or after birth (Lin, S. P., Youngson, N., Takada, S., Seitz, H., Reik, W., Paulsen, M., Cavaille, J., and Ferguson-Smith, A C. (2003).
- RNA-seq and gene expression analysis were performed following the methods described previously in Sections 1.10 and 1.7.
- Gapdh-F CACTCTTCCACCTTCGATGC
- Gapdh-R CTCTTGCTCAGTGTCCTTGC
- Igf2-F CTAAGACTTGGATCCCAGAACC
- Gtl2-F TTGCACATTTCCTGTGGGAC
- Gtl2-R AAGCACCATGAGCCACTAGG
- CTGTTGGTTGCGGCTACGAT H19-F CATGTCTGGGCCTTTGAA H19-R: TTGGCTCCAGGATGATGT
- Genome-wide methylation level analysis was performed following the method as described in Section 1.11.
- Target mutations mutations of Tet1, Tet2, Tet3, and p53 family
- sgRNAs of Tet1, Tet2, and Tet3 were annealed respectively, and ligated to a BbsI digested px330-mCherry plasmid respectively, and positive plasmids in which sgRNAs were ligated were picked up by sequencing.
- Tet1 sgRNA sequence (SEQ ID NO: 5) GGCTGCTGTCAGGGAGCTCA Tet2 sgRNA sequence: (SEQ ID NO: 6) GAAAGTGCCAACAGATATCC Tet3 sgRNA sequence: (SEQ ID NO: 7) AAGGAGGGGAAGAGTTCTCG
- the plasmids expressing the sgRNAs of Tet1, Tet2, and Tet3 were co-transformed into the DKO-AG-haESC cell line. mCherry positive cells were sorted, and plated in a Petri dish. After 5 days of growth, the clones were picked and passaged for amplification. The established cell line was identified for the Tet1, Tet2, and Tet3 mutations by sequencing the PCR product.
- Tet1 check-F GCCCCTGTTGTCTTATACGTT Tet1 check-R: CATTCGCCTCAGGACCAC Tet2 check-F: CCGCCACAAGAAAATATGTCC Tet2 check-R: AGCTAACTCTGGCAAACACC Tet3 check-F: CAGAGTGGCCTCAGTTTCCC Tet3 check-R: ACAACTTTTACCCAGGAGTCACAC
- sgRNAs of p53, p63, and p73 were annealed respectively, and ligated to a BbsI digested px330-mCherry plasmid respectively, and positive plasmids in which sgRNAs were ligated were picked up by sequencing.
- p53 sgRNA sequence (SEQ ID NO: 8) CACCTGGGCTTCCTGCAGTC p63 sgRNA sequence: (SEQ ID NO: 9) TGGGCCCGGGTAATCTGTGT p73 sgRNA sequence: (SEQ ID NO: 10) TGTCGATAGGAGTCAACCAA
- the plasmids expressing the sgRNAs of p53, p63, and p73 were co-transformed into the DKO-AG-haESCs cell line. mCherry positive cells were sorted, and plated in a Petri dish. After 5 days of growth, the clones were picked and passaged for amplification. The established cell line was identified for the p53, p63, and p73 mutations by sequencing the PCR product.
- P53 check-F CCCCTGTCATCTTTTGTCCCT
- P53 check-R AAGAGTTCCACGTCCCCTG
- P63 check-F CACACCAAATAATGCCAATT
- P63 check-R CAGACTCTCTTACCGTCCAG
- P73 check-F GACCCACTTCTAAACCTGCC
- Tet1, Tet2 and Tet3 were mutated in DKO-AG-haESCs by CRISPR-Cas9 method.
- the plasmids constructed to express Cas9 and 3 sgRNAs of Tet1, 2, and 3 ( FIG. 3A ) (see Wang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., and Jaenisch, R. (2013).
- Cell 153, 910-918 were transformed into DKO-AG-haESCs.
- 56 DKO-AG-haESC lines were finally established.
- sgRNAs of Tet1, and Tet3 were annealed and ligated to a BbsI digested px330-mCherry plasmid respectively, and positive plasmids in which sgRNAs were ligated were picked up by sequencing.
- pEGFP-N1 plasmid and pECFP-N1 plasmid were respectively used as a template (primers: P2A-fluorescence F: GCCACGAAGCAAGCAGGAGATGTTGAAGAAAACCCCGGGCCTGTGAGCAAGGGCG AGGAG
- P2A-fluorescence R CTTGTACAGCTCGTCCATG
- a sequence encoding EGFP or ECFP was amplified, and then correspondingly ligated to a multiclonal site on a pMD19-T vector, to obtain a pMD19-T-EGFP/ECFP vector.
- the left and right homologous arms of the gene of interest were respectively inserted into two sides of the EGFP or ECFP gene in the pMD19-T-EGFP/ECFP vector.
- TET1LA left homologous arm: (SEQ ID NO: 11)
- TET1 RA right homologous arm: (SEQ ID NO: 12)
- TET3 LA left homologous arm: (SEQ ID NO: 13)
- TET3 RA right homologous arm: (SEQ ID NO: 14)
- the 4 plasmids comprising plasmids carrying Tet1 and Tet3 sgRNA, and Tet1-EGFP and Tet3-ECFP donors were co-transfected into the DKO-AG-haESCs cell line.
- mCherry positive cells were sorted, and plated in a Petri dish. After 5 days of growth, the clones were picked and passaged for amplification.
- the established cell line was identified for the Tet1-EGFP and Tet3-ECFP knockins by PCR.
- the double knock-in cells were designated as Tet1&3-KI-DAH.
- Tet1 LA-F TTTGTGTCTATGAACTACCAGTGAG Tet1
- LA-F CAGGCCCGGGGTTTTCTTC Tet1
- RA-F CAACGAGAAGCGCGATCACA Tet1
- RA-F TTTTGACTGATCCCAATTTGCCT Tet3
- LA-F TGTTCACTGGTGAAGGCCAG Tet3
- LA-F GAACAGCTCCTCGCCCTTG Tet3
- LA-F TGAGCAAAGACCCCAACGAG Tet3 RA-R: ATCGACAAACTTTGGGGCGA
- sgRNA of Tet2 was annealed and ligated to a BbsI digested px330-mCherry plasmid, and a positive plasmid in which sgRNA was ligated was picked up by sequencing.
- Tet2-mCherry donor by using pmCherry-N1 as a template, and P2A-fluorescence F: GCCACGAAGCAAGCAGGAGATGTTGAAGAAAACCCCGGGCCTGTGAGCAAGGGCG AGGAG and P2A-fluorescence R: CTTGTACAGCTCGTCCATG as primers, a sequence encoding mCherry was amplified and then ligated to a pMD19-T carrier. Subsequently, the left and right homologous arms of the gene of interest were respectively inserted into two sides of the mCherry sequence in the pMD19-T-mCherry vector.
- TET2 LA left homologous arm: (SEQ ID NO: 15)
- TET2 RA right homologous arm: (SEQ ID NO: 16)
- the 2 plasmids comprising the plasmid carrying Tet2 sgRNA and the Tet2-mCherry donor were co-transfected into the Tet1&3-KI-DAH cell line.
- mCherry positive cells were sorted, and plated in a Petri dish. After 5 days of growth, the clones were picked and passaged for amplification. The established cell line was identified for the Tet2-mCherry knock-in by PCR. The positive cell clone was the Tet-TKI-DAH cell line.
- Tet2 LA-F CACACCCTTCACCAACAGACG
- Tet2 LA-R ATCTCGAACTCGTGGCCGTT
- Tet2 RA-F AAGACCACCTACAAGGCCAAG
- Tet2 RA-R GGTAGGCAAAGTGCTTTTCTAAGAC
- DKO-AG-haESCs were obtained in which endogenous Tet1, Tet2 and Tet3 were knocked in different fluorescent reporter groups.
- DKO-AG-haESCs were transfected with a plasmid co-expressing Cas9 and Tet1 and Tet3 sgRNAs ( FIG. 3A ) and a double stranded DNA donor vector having EGFP and ECFP reporter groups fused respectively to the last terminator of Tet1 and Tet3 ( FIGS. 3H and S 5 A).
- a total of 150 DKO-AG-haESC cell lines were obtained, with 10 Tet1-EGFP knock-in and 7 Tet3-ECFP knock-in cell lines ( Figs. S5B and S 5 C).
- Tet1 & 3-KI-DAH-1 Figs. S5D and S 5 E.
- ICAHCI results showed that DKO-AG-haESCs carrying Tet1-EGFP and Tet3-ECFP knock-ins have similar semi-cloned mice production capability to WT DKO-AG-haESCs ( Figs. S5F and S 5 G, Table 1 and Table S3).
- the plasmid expressing Cas9 and Tet2 sgRNA and the double-stranded DNA donor vector having the mCherry reporter group fused to the last terminator of the Tet2 gene were transfected into the Tet1 & 3-KI-DAH-1 cell line ( FIGS. 3A and 3H ).
- 8 red-KFP knock-in haploid cell lines were identified (designated as Tet-TKI-DAH-1 through Tet-TKI-DAH-8) ( FIGS. 31 and S 5 H).
- the developmental potential of the Tet-TKI-DAH cell line was verified by ICAHCI.
- Tet-TKI-DAH was able to efficiently produce viable semi-cloned mice by injection into oocytes ( Figs. S5S , S 5 J, Table 1, and Table S3). Taken together, these results indicate that it is a possible route to produce SC mice having corresponding genetic characteristics by ICAHCI after multi-gene genetic manipulation of DKO-AG-haESCs.
- the virus was prepared and DKO-AG-haESCs were infected with a genome-wide lentiviral sgRNA library, and then transfected with a pX330-mCherry plasmid expressing Cas9, to finally construct DKO-AG-haESCs carrying the sgRNA library.
- mice were constructed using the previously constructed cells as a donor for ICAHCI.
- the sgRNAs were detected by PCR amplification using specific primers, and then the PCR product was subjected to agar gel electrophoresis to observe the presence of a strip.
- Lenti-sg-F GTTACTCGAGCCAAGGTCGG
- Lenti-sg-R GACTCGGTGCCACTTTTTCA
- the corresponding gene inserted was identified, and then the upstream and downstream primers were designed by the conventional method in the vicinity of the target gene sgRNA, followed by PCR and sequencing.
- mice 4A this method is known as Lenti-sgRNA+pX330.
- This library had 87,897 sgRNAs designed for the genes of 19,150 encoded proteins in mice.
- 1.0 ⁇ 10 7 haploid cell line IG ⁇ DMR -H19 ⁇ DMR -AGH-1 enriched by FACS were infected with the genome-wide lentiviral sgRNA library. After 2 days, these infected cells were treated with puromycin for 7 days, followed by transfection with the pX330-mCherry plasmid expressing Cas9.
- Haploid cells expressing mCherry indicated the successful transfection and expression of Cas9, which were then used in ICAHCI experiments following FACS enrichment ( FIG. 4B ).
- CRISPR-Cas9 7 haploid cell clones were randomly selected. All of the detected cell clones carried one sgRNA, which was also found to be mutated by DNA sequencing, indicating that gene mutations can be successfully induced in haploid cells by CRISPR-Cas9.
- mice were obtained by three independent ICAHCI experiments ( FIG. 4E and Table 2), of which 82 carried one sgRNA ( FIG. 4F ). Sequencing of the PCR products of sgRNA revealed that 43 SC mice harbored one allelic mutation of the gene of interest, 39 of which carried insertions or knockouts mutation (indel) that result in frameshift, leading to the loss of function of one allele ( FIG. 4G ). Interestingly, all the mutations were of the same genotype, indicating that gene mutations are realized in haploid cells after the transient expression of Cas9. Although the remaining 39 mice carried one sgRNA, no DNA cleavage was shown at the site needed to be mutated.
- indel knockouts mutation
- DKO-AG-haESCs were infected with the lentiviral CRISPR-sgRNA library following the method as described in Section 1.5, to obtain a cell line carrying the lentiviral sgRNA library.
- the nuclei of the haploid cells carrying sgRNA were injected into mature oocytes by ICAHCI, followed by intracytoplasmic injection of Cas9 mRNA into the reconstructed oocyte (where this protocol was known as Lenti-sgRNA+Cas9 injection). Semi-cloned mice were then constructed by embryo transfer.
- sgRNA detection in semi-cloned mice The detection was carried out following the method as described in Example 9.
- Detection of allelic mutation The detection was carried out following the method as described in Example 9. In addition, the PCR product of the target gene was ligated into the pMD19-T vector, and then the clones were picked up and sequenced.
- haploid cells carrying sgRNA were injected into mature oocytes by ICAHCI and then Cas9 was injected into the reconstructed oocytes (where this protocol was known as Lenti-sgRNA+Cas9 injection).
- a total of 45 SC mice carrying one sgRNA were born, of which 22 had genetic mutations (Table 2).
- Sequencing of the PCR product of the gene of interest revealed that 10 mice had only a monoallelic modification, and other 12 mice were biallelic mutant (which is 23.5% of all born SC mice).
- Sequencing by TA cloning of the 7 biallelic mutant SC mice revealed that approximately 63% of the clones carried the insertion or deletion mutations (Table S4).
- the sgRNA-bearing haploid cells were constructed following the method as described in Example 10A and the pX330-mCherry plasmid was then transiently transfected into the sgRNA-bearing haploid cells.
- the nuclei of the haploid cells obtained in A were injected into oocytes by ICAHCI, followed by intracytoplasmic injection of Cas9 mRNA. Semi-cloned mice were then constructed by embryo transfer.
- sgRNA detection in semi-cloned mice The detection was carried out following the method as described in Example 9.
- the pX330-mCheny plasmid was transiently transfected into the sgRNA-bearing haploid cells, and then the cells were injected into oocytes, followed by injection of Cas9 mRNA (Fig. S 6 A and S 6 B) (where this protocol was known as Lenti-sgRNA+pX330+Cas9 injection).
- Fig. S 6 A and S 6 B where this protocol was known as Lenti-sgRNA+pX330+Cas9 injection.
- a total of 27 SC mice carrying one sgRNA were obtained. 22 mice carried genetic mutations (Figs. S 6 C and S 6 D and Table 2), in which 13 of the mutant mice carried biallelic mutations (Fig. S 6 E) (which was 41.9% of all the SC mice) and the other 9 mice were monoallelic mutant.
- TA cloning and sequencing results of 5 biallelic mutant mice revealed that about 79% of the clones have insertion or deletion mutations (Figs. S 6 F
- the cell line integrated with lentiviral Cas9 and lentiviral sgRNA library was further sorted by FACS to enrich the haploid cells for use in subsequent ICAHCI operation.
- mice were constructed by ICAHCI using DKO-AG-haESCs with constant expression of Cas9 and sgRNA library as a donor.
- Polm check-F TCCGATGGGAAGCCAAAAGC
- Polm check-R CGTACCGCAACCGCGAAGTA
- Scube1 check-F CCATAATAATCCACTTCCAT
- Scube1 check-R CCAACCCCTGTCCACTACCT
- DKO-AG-haESCs with constant expression of Cas9 and sgRNA library were obtained by two rounds of screening with drugs.
- SC mice were then generated by ICAHCI ( FIG. 5A-D ) (where this protocol was known as Lenti-Cas9+lenti-sgRNA).
- 272 (18.7%) of the 1,453 embryos reconstructed by ICAHCI were developed fully ( FIG. 5E ) and the birth rate was basically similar to that obtained with WT DKO-AG-haESCs or DKO-AG-haESCs carrying different gene modifications (Table 2), indicating that after multiple genetic manipulations, the ability of DKO-AG-haESCs to produce SC mice is not affected.
- FIG. 5F and Table 2 A total of 224 SC mice carried one sgRNA and were used for subsequent genotyping ( FIG. 5F and Table 2). The results showed that 143 SC mice are genetically mutated, of which 83 are biallelic mutant mice ( FIG. 5G ). 60 monoallelic mutant SC mice were obtained. Although Cas9 in these mice was supposed to be constantly expressed, silencing of the viral vector led to transcriptional silencing of Cas9 at different development stages of the SC mice. TA cloning and sequencing of 26 biallelic mutant SC mice showed that about 66.3% of the clones have insertion or deletion mutations ( FIGS. 5H and I).
- AG-haESCs derived from the prior art, supplied by the author of (Yang, H., Shi, L., Wang, B. A., Liang, D., Zhong, C., Liu, W., Nie, Y., Liu, J., Zhao, J., Gao, X., et al. (2012). Generation of genetically modified mice by oocyte injection of AG-haESCss. Cell 149, 605-617).
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Environmental Sciences (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
- The present invention relates to biotechnologies, and specifically to an androgenetic haploid embryonic stem cell (AG-haESC), and a preparation method and use thereof.
- Genome-wide recessive genetic screening is an extremely effective and powerful method of identifying the functions of a gene involved in a given biological process. This strategy has been successfully used in lower organisms such as Saccharomyces cerevisiae and nematodes. In mammals, this functional screening is exceptionally difficult due to the diploidy of the genome (Shi, L., Yang, H., and Li, J. (2012). Haploid embryonic stem cells: an ideal tool for mammalian genetic analyses. Protein &
cell 3, 806-810). The means of targeting RNA interference (RNAi) at mRNA level has now become an optimal solution for genome-wide loss-of-function genetic screening in mammalian cells. However, this method often cannot effectively inhibit the gene expression, while there is an off-target effect (Kaelin, W. G., Jr. (2012). Molecular biology. Use and abuse of RNAi to study mammalian gene function. Science 337, 421-422). Recently, the bacterial-derived CRISPR-Cas9 system has been successfully used in the screening of genetic defects of the mouse and human at cellular levels. However, CRISPR-Cas9-mediated genome-wide screening is only used at cellular level, which limits the study exclusively to phenotyping at cellular level. In this regard, as currently done with lower organisms such as yeast and nematodes, it is important to achieve efficient, large-scale loss-of-function screening of a broader range of biological processes in mammalian systems. - The obtaining of mammalian haploid embryonic stem cells (haESCs) (Elling, U., Taubenschmid, J., Wirnsberger, G., O'Malley, R., Demers, S. P., Vanhaelen, Q., Shukalyuk, A. I., Schmauss, G., Schramek, D., Schnuetgen, F., et al. (2011). Forward and reverse genetics through derivation of haploid mouse embryonic stem cells. Cell Stem Cell 9, 563-574; and Leeb, M., and Wutz, A. (2011). Derivation of haploid embryonic stem cells from mouse embryos. Nature 479, 131-134) provides a desirable tool for genetic analysis. The androgenetic haploid embryonic stem cells (AG-haESCs) have a whole genome derived from spermatid, with which the full development of a reconstructed embryo can be achieved by intracytoplasmic AG-haESCs injection (ICAHCI) into mature MII oocytes, thereby obtaining a viable animal subject that is referred to as semi-cloned animal. It is inferred that if semi-cloned mice can be produced with AG-haESCs efficiently and stably by ICAHCI, important genes involved in a particular developmental process can be screened out by using AG-haESCs as fertilizing vectors to carry genome-wide CRISPR-Cas9 knockout library.
- However, previous studies have shown that the birth rate of viable, semi-cloned mice is very low (where the birth rate is 4.5% for half-cloned mice and 1% for semi-cloned rats), while approximately 50% of the semi-cloned mice exhibit a phenotype of retarded developmental, and are died shortly after birth. Furthermore, with the long-term culture of AG-haESCs, the overall birth rate of semi-cloned mice declines rapidly, especially for the additional culture resulting from genetic manipulation.
- One of the possible reasons is the abnormal expression of imprinted genes. These imprinted genes that are expressed in a parent-of-origin-specific manner are considered as an important barrier to the development of uniparental embryos, so that the normal growth and development of embryos require both the maternal and paternal genomes. At present, about 150 imprinted genes have been identified in mice, most of which are located in a large cluster of genes and are regulated by differentially methylated regions (DMRs) (Bartolomei, M. S. (2009). Genomic imprinting: employing and avoiding epigenetic processes. Genes &
development 23, 2124-2133). Consistent with this hypothesis, studies have shown that the imprinting of differentially methylated region (DMR) in which the imprinted gene H19 with inhibited paternal expression located is consistently abnormally erased in both AG-haESCs and growth-arrested, semi-cloned mice (Yang, H., Shi, L., Wang, B. A., Liang, D., Zhong, C., Liu, W., Nie, Y., Liu, J., Zhao, J., Gao, X., et al. (2012). Generation of genetically modified mice by oocyte injection of androgenetic haploid embryonic stem cells. Cell 149, 605-617). The maternally expressed H19 gene is adjacent to the paternally expressed Igf2, and both of them are regulated by the same DMR. This DMR is amenable to DNA methylation in the paternal allele, and as a CTCF-dependent insulator, permits the expression of the maternal allele only. The methylation state of this DMR determines whether H19 (where H19 is expressed, DMR is demethylated, and the insulator is activated) or Igf2 (where Igf2 is expressed, DMR is methylated, and the insulator is deactivated) is expressed. Interestingly, knockout of the H19 gene or its DMR does not lead to any severe phenotype in mice (Leighton, P. A., Ingram, R. S., Eggenschwiler, J., Efstratiadis, A., and Tilghman, S. M. (1995). Disruption of imprinting caused by deletion of the H19 gene region in mice. Nature 375, 34-39; and Thorvaldsen, J. L., Mann, M. R., Nwoko, O., Duran, K. L., and Bartolomei, M. S. (2002). Analysis of sequence upstream of the endogenous HI9 gene reveals elements both essential and dispensable for imprinting. Molecular and cellular biology 22, 2450-2462). At present, there are related researches on reconstructed embryos obtained by using fully mature oocytes and genetically modified immature oocytes (Kono, T., Obata, Y., Wu, Q., Niwa, K., Ono, Y., Yamamoto, Y., Park, E. S., Seo, J. S., and Ogawa, H. (2004). Birth of parthenogenetic mice that can develop to adulthood. Nature 428, 860-864; and Kawahara, M., Wu, Q., Takahashi, N., Morita, S., Yamada, K., Ito, M., Ferguson-Smith, A C., and Kono, T. (2007). High-frequency generation of viable mice from engineered bi-matemal embryos. Nature biotechnology 25, 1045-1050). However, the immature oocytes cannot be cultured and expanded in vitro, so the in-vitro genetic modification cannot be realized; and the technique of obtaining reconstructed embryos from fully-matured oocytes and genetically modified immature oocytes is difficult in operation, so the application value is not high. - In view of the disadvantage of low birth rate of semi-cloned animals in the prior art, an object of the present invention is to provide an androgenetic haploid embryonic stem cell (AG-haESC) that can enhance the birth rate of semi-cloned animals and use thereof.
- The most possible cause of low birth rate is the occurrence of abnormal imprinting status of the androgenetic haploid. It is surprisingly found through experiments that characteristics of the AG-haESCs resembling those of a round spermatid can be established by knocking out the differentially methylated regions (DMRs) of two imprinted clusters H19-Igf2 and Dlk1-Dio3. Such AG-haESCs with two DMRs knocked out is designated as DKO-AG-haESCs. With the DKO-AG-haESCs, semi-cloned mice can be obtained effectively (with a birth rate of SC mice of about 20%), and semi-cloned animals with multiple genetic modifications can still be produced stably after in-vitro genetic manipulation of the AG-haESCs. Unexpectedly, a large number of mutant animals can be effectively obtained in one step simply by transfecting the DKO-AG-haESCs with stable expression of sgRNA library and Cas9 in vitro at the cellular level. These experimental results show that DKO-AG-haESCs can be used as an intermediate to achieve gene mutation at the individual level by carrying the sgRNA library and therefore can be further used in gene mutation-based large-scale screening at individual animal level.
- A first aspect of the present invention provides an AG-haESC, in which H19 DMR and IG-DMR genes are knocked out.
- A second aspect of the present invention provides a method for preparing the AG-haESC, which comprises knocking out H19 DMR and IG-DMR from an AG-haESC, to obtain the above mentioned AG-haESC.
- A third aspect of the present invention provides use of the AG-haESC in constructing a genetically modified semi-cloned animal.
- A fourth aspect of the present invention provides a method for constructing a genetically modified semi-cloned animal, which comprises combining an AG-haESC in which H19 DMR and IG-DMR genes are both knocked out with an oocyte to obtain a semi-cloned embryo, and incubating the semi-cloned embryo, to obtain a semi-cloned animal.
- A fifth aspect of the present invention provides a genetically modified animal, which is constructed according to the above method, or is a sexually reproduced offspring of a semi-cloned animal constructed according to the above method.
- A sixth aspect of the present invention provides a method for constructing a genetically modified semi-cloned animal library with the AG-haESCs according to the present invention and a lentiviral sgRNA library.
- A seventh aspect of the present invention provides a genetically modified semi-cloned animal library constructed by using the above method.
- The present invention has the following beneficial effects.
- (1) Existing studies show that semi-cloned animals can be obtained from AG-haESCs established with haploid blastocyst by ICAHCI. However, AG-haESCs cannot produce viable SC animals after long-term subculture, especially after in vitro genetic manipulation, probably due to the loss of male imprinted genes. It is found in the present invention that the AG-haESCs is capable of obtaining characteristics resembling a round spermatid by knocking out H19 and IG-DMR. Upon injection into an oocyte, a viable SC mouse is stably obtained with AG-haESCs at a rate of about 20%, which is about 10 times of the rate obtained with earlier generation of WT AG-haESCs (Yang et al., 2012). Importantly, it is also found in the present invention that DKO-AG-haESCs can be effectively used for multi-gene genetic manipulation, and SC mice with multiple genetic modifications can be further obtained by ICAHCI. More importantly, by incorporating with a sgRNA library, DKO-AG-haESCs can be effectively used in one-step generation of heterozygous and homozygous mutant mice, providing further evidence for gene knockout-based screening at animal individual level.
- (2) DKO-AG-haESCs are advantageous over the existing methods for obtaining genetically modified animals in the following aspects. Firstly, existing studies report the one-step production of transgenic mice or mice with endogenous genetic mutations by direct injection of Cas9 mRNA and sgRNA into fertilized eggs. This method demonstrates the strong potential of CRISPR-Cas9 technique in the production of genetically modified animals. However, there is an extremely high rate of chimerism observed in the genetically manipulated animals so far, which greatly increases the difficulty of phenotyping in F1 generation of animals. In contrast, DKO-AG-haESCs-mediated gene editing technology provides a unique set of system for well phenotyping and screening genetically modified DKO-AG-haESCs, to ensure that the resulting SC animals exhibit the expected genetic traits, so the occurrence of chimerism can be largely avoided. Secondly, genetically modified mice obtained by conventionally injecting diploid embryonic stem cells into the blastocysts need to experience the germline transmission of chimeric mice. However, the step of germline transmission is often very time-consuming. More seriously, the diploid embryonic stem cells with multiple genetic modifications may exhibit trait segregation in their offspring during germline transmission. Only a small percentage of offspring may contain all the desired genetic modifications. In contrast, F0 mice with multiple genetic modifications can be obtained with DKO-AG-haESCs in one step. Thirdly, fully ESC-derived mice can be obtained in one step by injecting diploid embryonic stem cells into the tetraploid blastocysts (also known as tetraploid complementation technique). This method is also widely used and is the most stringent standard for testing the pluripotency of reprogrammed cells such as induced pluripotent stem cells (iPSCs) and nuclear transfer embryonic stem cells (ntESCs). However, the birth rate of the embryonic stem cell (ESC)- or iPSC-derived animals is very low, probably due to the epigenetic instability of diploid embryonic stem cells. In contrast, animals can still be stably and efficiently obtained with DKO-AG-haESCs after long-term in vitro culture, especially genetic manipulation. Fourthly, the ICAHCI technology is similar to ROSI that is a sophiscated technology for various mammals, including non-human primates and human. Cynomolgus monkey-derived haploid embryonic stem cell line has now been successfully established and the ICAHCI technology may be used in the near future to efficiently and rapidly obtain genetically modified non-human primates. Lastly, a large number of genetically mutated animals can be obtained with DKO-AG-haESCs by incorporating with a sgRNA library. Obviously, this method is simpler and less labor-intensive than direct injection of plasmids or mRNAs into embryos for the large-scale production of mutant animals, since the DKO-AG-haESC line, which carries constantly expressed Cas9 and sgRNA library, can repeatedly serve as a donor for injection, to produce various genetically mutated animals continuously and effectively. These various mutant animals can be easily and quickly identified for the sgRNA insertion (which is exactly a barcode for a mutant animal) by PCR using a universal pair of primers. In contrast, the method of injecting plasmids or mRNAs directly into embryos requires separate preparation of sgRNAs for each individual injection. The mutant animals obtained need to be housed separately, and the subsequent identification requires the use of corresponding primers for a particular gene. It is conceivable that some of the differentially expressed genes obtained from an appropriate sgRNA library, such as those obtained by high-throughput analysis at the cellular level, can be classified into a sub-library of sgRNAs that may be involved in a particular stage of development. By using the DKO-AG-haESC solution, important genes related to this development process can be rapidly and effectively screened out at the individual level.
- (3) Production of DKO-AG-haESC-mediated SC animals is an effective and simple way to generate animal models that carry genetic modifications such as multiple genetic mutations or multiple gene knockins in a gene family. Moreover, by incorporating with a sgRNA library, a large number of genetically mutated animals can be obtained in one step with DKO-AG-haESCs. Although the underlying mechanism that DKO-AG-haESCs is so effective in the production of SC animals is still unknown, this approach may be able to facilitate the deeper exploration for the developmental process and complex diseases.
-
FIG. 1A is a view schematically showing the production of SC mice by intracytoplasmic AG-haESCs injection (ICAHCI) of AG-haESCs bearing 2 DMR knockouts. -
FIG. 1B shows androgenetic haploid embryos produced by injection of H19ΔDMR spermatids into enucleated MII oocytes. -
FIG. 1C shows one of the AG-haESC lines established with an androgenetic haploid blastocyst. -
FIG. 1D shows H19ΔDMR AG-haESCs (H19ΔDMR -AGH-1) established by multiple FACS enrichments of haploid cells. -
FIG. 1E shows SC mice produced with H19ΔDMR -AGH-1 (p8) by ICAHCI. -
FIG. 1F is a view schematically showing an IG-DMR knockout sgRNA sequence. -
FIG. 1G shows production of H19ΔDMR -IGΔDMR -AGH-1 cell line. Left panel: collected mCherry positive cells plated in a Petri dish. Right panel: established H19ΔDMR -IGΔDMR -AGH cell line (H19ΔDMR -IGΔDMR -AGH-4). -
FIG. 1H shows SC mice produced with H19ΔDMR -IGΔDMR -AGU-4 (p29) by ICAHCI. - Fig. S1A shows genotyping of H19Δ
DMR -AGH cell line. - Fig. S1B shows that 80% of the embryos reconstructed with H19Δ
DMR -AGH cells reach 2-cell embryos, which is similar to the developmental rate obtained upon round spermatid injection (ROSI). - Fig. S1C shows SC mice produced with H19Δ
DMR -AGH-1, 2, 3 cell lines by ICAHCI, in which asterisk represents growth-arrested SC mice. - Fig. S1D shows genotyping of H19Δ
DMR -AGH cell-derived SC mice. - Fig. S1E shows expression analysis of imprinted gene (Gtl2 and Dlk1) in various organs of H19Δ
DMR -AGH cell-derived normal and growth-arrested SC mice. - Fig. S1F shows severely erased methylation imprinting of IG-DMR in growth-arrested SC mice.
- Fig. S1G shows Cobra assay of IG-DMR in growth-arrested and normal SC mice.
- Fig. S1H shows methylation state of IG-DMR in H19Δ
DMR -AGH cell line. -
FIG. 2A shows semi-cloned mice produced with IGΔDMR -AGH-1 cell line (P17), in which asterisk represents growth-arrested SC mice, which die shortly after birth. -
FIG. 2B shows methylation state of H19 DMR in normal and abnormal SC mice produced with IGΔDMR -AGR-1 cell line. -
FIG. 2C schematically shows H19 DMR knockout sgRNAs designed. -
FIG. 2D shows genotyping of H19ΔDMR -IGΔDMR -AGH-OG3 cell lines, produced by knocking out H19 and IG-DMRs from AGH-OG3 cell line. -
FIG. 2E shows genotyping of offspring obtained by mating SC mice produced with DKO-AG-haESCs, where the offspring carrying IG-DMR die before or shortly after birth. -
FIG. 2F shows analysis of gene expression profile of DKO-AG-haESCs by RNA-seq. The gene expression profile is clustering of the expression of all genes. The three DKO-AG-haESC cell lines show a gene expression profile that is similar to that of the AG-haESCs in the control group, but very different from that of the round spermatid. To avoid the effect of haploid diploidization on the expression profile, G0/G1 cells are collected by FACS for RNA-seq. -
FIG. 2G shows imprinted gene expression profile of DKO-AG-haESCs. The expression profiles of three different DKO-AG-haESC lines are similar to that of the AG-haESCs in the control group, but different from that of the round spermatids in mice -
FIG. 2H shows analysis of methylation in DKO-AG-haESCs by RRBS. - Fig. S2A shows genotyping of H19Δ
DMR -IGΔDMR -AGH cell line obtained by knocking out IG-DMR from H19ΔDMR -AGH cells. - Fig. S2B shows the sequencing result of a DKO-AG-haESC cell line (H19Δ
DMR -IGΔDMR -AGH-4). - Fig. S2C shows 2-cell embryos obtained with H19Δ
DMR -IGΔDMR -AGR cells by ICAHCI. - Fig. S2D shows genotyping of SC mice, where H19Δ
DMR -IGΔDMR -AGH-4-derived SC mice all have H19 and IG DMR knockouts. - Fig. S2E shows SC mice produced with IGΔ
DMR -AGH-2 (p8). - Fig. S2F shows the methylation state of H19 DMR in IGΔ
DMR -AGH cells. - Fig. S2G shows the methylation state of H19 DM in IGΔ
DMR -AGH-2-derived normal and growth-arrested SC mice. - Fig. S2H shows sequencing of a DKO-AG-haESC cell line (IGΔ
DMR -H19ΔDMR -AGH-2). - Fig. S2I shows SC mice produced with IGΔ
DMR H19ΔDMR -AGH-2 cells (p24) by ICAHCI. -
FIG. 52J shows genotyping of IGΔDMR -H19ΔDMR -AGR-2-derived SC mice. -
FIG. 3A is a view schematically showing Tet1, Tet2 and Tet3 sgRNAs. -
FIG. 3B shows mCherry positive cells collected by FACS, which are plated in a Petri dish, to obtain DKO-AG-haESCs with mutant Tet family of genes. -
FIG. 3C shows a Tet-TKO-DAH cell line obtained. -
FIG. 3D shows sequencing of Tet1, Tet2 and Tet3 in the Tet-TKO-DAH cell line. -
FIG. 3E shows sequencing of PCR products of Tet1, Tet2 and Tet3 genes in SC mice produced with Tet-TKO-DAH-1 and Tet-TKO-DAH-2 cell lines. -
FIG. 3F is a view schematically showing p53, p63 and p73 sgRNAs. -
FIG. 3G shows sequencing of p53, p63 and p73 in p53-TKO-DAH-2 cell line. -
FIG. 3H is a view schematically showing Tet1-EGFP, Tet2-mCherry, and Tet1-ECFP double-stranded DNA vectors, in which EGFP, mCherry, and ECFP are respectively fused to a stop codon of Tet1, Tet2, and Tet3. -
FIG. 3I shows genotyping of Tet-TKO-DAH-1 cell line. - Fig. S3A shows sequencing of 2 DKO-AG-haESCs cell lines (H19Δ
DMR -IGΔDMR -AGH-OG3-1 and H19ΔDMR -IGΔDMR -AGH-OG3-1) obtained by knocking out H19 and IG-DMR from WT-AG-haESCs (AGH-OG3). - Fig. S3B shows SC mice produced with H19Δ
DMR -IGΔDMR -AGU-OG3-1 (p26) by ICAHCI. - Fig. S3C shows genotyping of SC mice produced with H19Δ
DMR -IGΔDMR -AGH-OG3-2 cell line. - Fig. S3D shows expression analysis of imprinted gene (H19, Igf2, Gtl2 and Dlk1) in DKO-AG-haESCs and normal AG-haESCs, where after H19 and IG-DMR are knocked out, the expression of H19 and Gtl2 in AGH-OG-3 is down regulated, while the expression of Igf2 and Dlk1 is up regulated.
- Fig. S3E shows bigwig track of H19 and Gtl2. The RNA-seq result shows that compared with WT-AG-haESCs, the expression level of H19 and Gtl2 in DKO-AG-haESCs is much lower.
- Fig. S3F shows the methylation levels in H19-Igf2 and Dlk1-Dio3 imprinted cluster regions.
- Fig. S3G shows the methylation state of imprinted genes in DKO-AG-haESCs, WT-AG-haESCs, and round spermatids.
-
FIG. 4A is a view schematically showing a large number of heterozygous mutant SC mice produced with DKO-AG-haESCs carrying sgRNA library by ICAHCI. -
FIG. 4B represents mCherry-positive haploid cells successfully transfected with Cas9 enriched by FACS for subsequent ICAHCI. -
FIG. 4C shows PCR identification of sgRNAs in single cell derived haploid clones, where the tested cell clones all carry sgRNAs. -
FIG. 4D shows sequencing of different mutant genes in cell clones, where the tested cell clones all have modifications of the genes of interest. -
FIG. 4E shows SC mice derived from DKO-AG-haESCs carrying sgRNA library. -
FIG. 4F shows PCR identification of sgRNAs in SC mice. -
FIG. 4G shows sequencing of different mutant genes of interest in SC mice, where all the tested SC mice have modifications of the genes of interest. - Fig. S4A shows sequencing of Tet1, Tet2 and Tet3 in Tet-TKO-DAH-3 cell line.
- Fig. S4B shows SC mice produced with Tet-TKO-DAH-3 (p36) by ICAHCI.
- Fig. S4C shows sequencing of p53, p63 and p73 in p53-TKO-DAH-1 cell line.
- Fig. S4D shows SC mice produced with p53-TKO-DAH-1 cell line (p44) by ICAHCI.
- Fig. S4E shows sequencing of p53, p63 and p73 in SC mice produced with p53-TKO-DAH-1 and p53-TKO-DAH-2 cell line.
-
FIG. 5A is schematic representation of a large number of bi-allelic mutant SC mice produced by ICAHCI with DKO-AG-haESCs that carry consistently expressed Cas9 and sgRNA library. -
FIG. 5B shows PCR analysis of Cas9 in single cell-derived cell clone, where all tested cell clones comprises the Cas9 transgene. -
FIG. 5C shows quantitative PCR analysis of Cas9 in single cell-derived cell clones. -
FIG. 5D shows PCR identification of sgRNAs in single cell-derived cell clones. -
FIG. 5E shows SC mice derived from DKO-AG-haESCs that carry constantly expressed Cas9 and sgRNA library. -
FIG. 5F shows PCR identification of sgRNAs in SC mice. -
FIG. 5G shows bi-allelic mutant SC mice produced by ICAHCI with DKO-AG-haESCs that carry constantly expressed Cas9 and sgRNA Library, in which the Polm bi-allelic mutant SC mice are taken as an example. -
FIG. 5H shows analysis of the polm gene mutation in the mouse tail by TA cloning and sequencing, where 24 out of 26 tested clones have a frameshift mutation. -
FIG. 5I shows summary of TA cloning and sequencing results of 7 bi-allelic mutant SC mice, in which more than 80% of the clones have insertion or deletion mutations. -
FIG. 5J shows TA cloning and sequencing of different organs in Scube1 bi-allelic mutant SC mice. - Fig. S5A is a view schematically showing Tet1-EGFP, Tet2-mCherry, and Tet3-ECFP exogenous double-stranded vectors.
- Fig. S5B shows genotyping of Tet1-EGFP knock-in DKO-AG-haESCs.
- Fig. S5C shows genotyping of Tet3-ECFP knock-in DKO-AG-haESCs.
- Fig. S5D shows genotyping of Tet1&3-KI-DAH-1 cell line.
- Fig. S5E shows sequencing of Tet1-EGFP and Tet-ECFP in Tet1&3-KI-DAH-1 cell line.
- Fig. S5F shows 3-week-old SC mice produced with Tet1&3-KI-DAH-1 cell line (p40) by ICAHCI.
- Fig. S5G shows genotyping of SC mice produced with Tet1&3-KI-DAH-1 cell line.
- Fig. S5H shows sequencing of Tet2-mCherry in Tet-TKI-DAH-1 cell line.
- Fig. S5I shows SC mice produced with Tet-TKI-DAH-2 cell line (p50).
- Fig. S5J shows genotyping of SC mice produced with Tet-TKI-DAH-1 cell line.
- Fig. S6A shows bi-allelic mutant mice produced by injecting haploid cells transiently treansfected with pX330-mCheny plasmid and carrying sgRNAs into mature oocytes and then injecting Cas9 mRNA to the reconstructed oocytes (where the protocol is known as Lenti-sgRNA+pX330+Cas9 injection).
- Fig. S6B shows PCR identification of sgRNA insertion into single cell-derived haploid ES clones.
- Fig. S6C shows SC mice produced with DKO-AG-haESCs carrying sgRNA library.
- Fig. S6D shows PCR identification of sgRNAs in SC mice.
- Fig. S6E shows bi-allelic mutant mice produced by injecting DKO-AG-haESCs carrying sgRNA library into oocytes, and then injecting Cas9 mRNA to SC embryos, in which bi-allelic mutant mice carrying Slco5al gene are taken as an example.
- Fig. S6F shows TA cloning and sequencing of tails of mice carrying Slco5al gene, where 18 out of the 20 tested clones have insertion or deletion mutations.
- Fig. S6G shows summary of TA cloning and sequencing results of 4 bi-allelic mutant mice.
- The present invention provides an androgenetic haploid embryonic stem cell (AG-haESC), in which H19DMR and IG-DMR are knocked out.
- The AG-haESCs have a whole genome derived from spermatid, has the self-replication ability and pluripotency of stem cells, and can replace the spermatid to combine with oocytes to support the full development of embryos.
- H19 DMR refers to a differentially methylated region (DMR) within the H19-Igf2 imprinted cluster. The specific location and sequence of H19 DMR can be determined according to the existing methods such as methylation sequencing or homologous sequence analysis and prediction. Human H19DMR is known to be located in the 1p15.5 region of the
chromosome 1 and the mouse H19 DMR is located at the distal end ofchromosome 7 between the two genes H19 and Igf2, a position from 2 kb to 4 kb upstream of the H19 gene. H19 DMR is methylated on the paternal allele, resulting in the inability of CTCF protein to bind to this methylated region so that the enhancer downstream of H19 does not need to cross over the obstacle CTCF, thereby increasing the expression of upstream Igf2 and decreasing the H19 expression. H19 DMR is demethylated on the maternal allele, and the CTCF protein is able to bind to this unmethylated region, so the enhancer downstream of H19 can only increase the H19 expression, and cannot regulate the upstream Igf2. If the paternal H19 DMR is knocked out, the enhancer downstream of H19 can upregulate the expression of Igf2. Since the androgenetic haploid is of paternal origin, theoretically it should be in a completely methylated state. However, studies show that the H19 DMR in the androgenetic haploid cultured in vitro suffers from abnormally erased methylation, and becomes demethylated, so that the expression of H19 is abnormally up-regulated and the expression of Igf2 is down-regulated. In the present invention, H19 DMR is knocked out and the abnormal state in which H19 expression is up-regulated and the Igf2 expression is down-regulated is corrected. - IG-DMR refers to a differentially methylated region (DMR) within the Dlk-Dio3 imprinted cluster. The specific location and sequence of IG DMR can be determined according to the existing methods such as methylation sequencing or homologous sequence analysis and prediction. The mouse IG-DMR is known to be located on the
chromosome 12 in a 4.15 kb repeat between the genes Dlk1 and Gtl2 in the imprinted cluster, and the human IG-DMR is located on the chromosome 14 (14q32.2). IG-DMR is DNA methylated on the paternal allele, so the gene Gtl2 and some micromRNAs in this imprinted cluster are not expressed while the gene Rtl1, Dlk1 and Dio3 are expressed. IG-DMR is un-DNA methylated (in demethylated state) on the maternal allele, so Gtl2 and some micromRNAs are expressed while the gene Rtl1, Dlk1 and Dio3 are not expressed. In the androgenetic haploid (of paternal origin) and SC animals born abnormal, studies show that the normally methylated IG-DMR suffers from abnormally erased methylation, causing the silencing of the genes Rtl1, Dlk1, and Dio3, and the abnormal activation of Gtl2 and some microRNAs. - Further, the AG-haESCs undergo other genetic modifications in addition to H19 DMR and IG-DMR knockouts.
- Specifically, genetic modification refers to the structural change of a gene made by a biological, chemical or physical means compared with that before modification, and this change mainly refers to the change in base pair composition, comprising, but not limited to, changes caused by the replacement, insertion, and deletion of one or more base pairs.
- In a preferred embodiment, the genetic modifications of Tet1, Tet2, Tet3 and p53 family of genes are exemplified.
- The AG-haESCs are derived from mammals, comprising human or non-human mammals. Preferably, the AG-haESCs are derived from a rodent, such as rabbit and murine that may be a mouse or a rat. In a preferred embodiment, the AG-haESCs are derived from mice.
- Compared with AG-haESCs in which H19 DMR and IG-DMR are not both knocked out, the birth rate of semi-cloned animals constructed with the AG-haESCs of the present invention is higher.
- The present invention also provides a method for preparing the AG-haESCs, which comprises knocking out the H19 DMR and IG-DMR from AG-haESCs, to obtain the AG-haESCs.
- The H19 DMR and IG-DMR can be knocked out by using an existing gene editing method. In a preferred embodiment, the H19 DMR and IG-DMR are knocked out using CRISPR/Cas9-mediated gene manipulation. Gene knockouts may also be performed by other methods, and the present invention is not limited to the methods listed in the examples.
- Due to the H19 DMR knockout, the complete sequence of H19 DMR is removed from the chromosome DNA; and due to the IG DMR knockout, the complete sequence of IG-DMR is removed from the chromosome DNA.
- In an embodiment, H19 DMR knockout AG-haESCs are constructed firstly, and then IG-DMR is further knocked out. In another embodiment, IG-DMR knockout AG-haESCs are constructed firstly and then H19 DMR is further knocked out. In another example, AG-haESCs in which H19 DMR and IG-DMR are both knocked out are directly constructed.
- Further, the AG-haESCs also undergo other genetic modifications.
- Such other genetic modifications refer to genetic modifications other than H19 DMR and IG-DMR knockouts. Such other genetic modifications may be the modification of a single target gene or the modifications of multiple target genes of interest. The target gene of interest is not specific and can be set and modified as desired in the research. For example, such other genetic modifications may be the modifications of one, two or more target genes. The AG-haESCs of the present invention in which H19 DMR and IG-DMR are both knocked out can be passaged in vitro, and thus they can theoretically be genetically modified constantly. The number of modifications made to the target gene can be set as needed without particular limitation.
- The genetic modifications comprise, but are not limited to, knock-in and knock-out of a target gene, and the like. The knock-in and knock-out of a target gene may be accomplished by techniques such as gene targeting and homologous recombination, comprising, but not limited to, genetic manipulation based on ZFN (zinc finger nuclease), TALEN (transcriptional activator-like effector nuclease) and CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats).
- In an embodiment, the AG-haESCs in which the H19 DMR and IG-DMR are both knocked out undergo one or more genetic modifications to obtain the AG-haESCs with H19 DMR and IG-DMR knockouts and with other genetic modifications. Alternatively, AG-haESCs can be genetically modified first, followed by knocking out H19DMR and IG-DMR from the genetically mutated AG-haESCs. In addition to the above, other biotechnological means that can achieve the H19 DMR and IG-DMR knockouts and other genetic mutations can also be used to construct the AG-haESCs with H19 DMR and IG-DMR knockouts and with other genetic modifications.
- The present invention also provides the use of the AG-haESCs in constructing genetically modified semi-cloned animals. Further, the AG-haESCs are used as a fertilizing vector in place of spermatid in the construction of genetically modified animals.
- The present invention also provides a method for constructing a genetically modified semi-cloned animal, which comprises: combining an AG-haESC in which H19 DMR and IG-DMR are both knocked out with an oocyte to obtain a semi-cloned embryo, and incubating the semi-cloned embryo to obtain a semi-clone animal.
- In general, the oocytes and the AG-haESCs are derived from the same kind of animal, preferably the same species of animal.
- The semi-cloned embryo may specifically be an semi-cloned embryo obtained by ICAHCI using the AG-haESCs in which H19 DMR and IG-DMR are both knocked out as a donor for ICAHCI.
- Further, the semi-cloned animal can be obtained by incubating the semi-cloned embryo in a suitable female organism by embryo transfer. In a preferred embodiment, the suitable maternal is a pseudopregnant ICR female rat.
- Further, the AG-haESCs undergoes other genetic modifications.
- The present invention further provides a genetically modified animal, which is constructed according to the above method, or is a sexually reproduced offspring of a semi-cloned animal constructed according to the above method.
- The semi-cloned animal according to the present invention may be a non-human mammal. Preferably, the semi-cloned animal is a rodent, such as rabbit or murine. In a preferred embodiment, the semi-cloned animal is a mouse.
- The present invention also provides a method for constructing a genetically modified semi-cloned animal library, which comprises the steps of:
- 1) infecting the AG-haESCs according to the present invention with virus particles prepared with the lentiviral sgRNA library plasmids, to obtain an AG-haESC library carrying the sgRNA library;
- 2) obtaining a semi-cloned embryo library by ICAHCI using a vector expressing Cas9 and/or Cas9 mRNA, with AG-haESCs in the AG-haESC library carrying the sgRNA library as a donor for ICAHCI; and
- 3) incubating the embryos in the semi-cloned embryo library to obtain a semi-cloned animal library.
- The sgRNA lentiviral library plasmids comprise several lentiviral vectors that express different sgRNAs. The lentiviral sgRNA library can be constructed by current technologies, or existing lentiviral sgRNA library plasmids may be used. Specifically, sgRNAs designed for different genes can be cloned into lentiviral vectors. The sgRNA can be designed according to the gene of interest.
- In a preferred embodiment, a commercially available lentiviral sgRNA library of whole genomes of mice is employed.
- Specifically, Step 2) may be selected from any one of:
- Method A:
- The AG-haESC library carrying the sgRNA library is further transfected with a plasmid expressing Cas9, and the semi-cloned embryos are obtained by ICAHCI using the resultant AG-haESCs as a donor for ICAHCI.
- Method B:
- AG-haESCs in the AG-haESC library carrying the sgRNA library, as a donor for ICAHCI, are injected into mature oocytes by ICAHCI, and then Cas9 mRNA is injected into the reconstructed oocytes, to obtain the semi-cloned embryos.
- Method C:
- The AG-haESC library carrying the sgRNA library is further transfected with a plasmid expressing Cas9, the resultant AG-haESCs, as a donor for ICAHCI, are injected into mature oocytes by ICAHCI, and then Cas9 mRNA is injected into the reconstructed oocytes, to obtain the semi-cloned embryo, from which a semi-cloned animal is obtained after embryo transfer.
- In the methods A and C, the plasmid expressing Cas9 can be constructed by cloning the Cas9 expressing gene into an expression plasmid. In a preferred embodiment, the plasmid expressing Cas9 is pX330-mCherry plasmid. The plasmid that is constructed to express Cas9 is not limited to the pX330 plasmid. The expression plasmid only needs to be suitable for expression of exogenous genes in mammalian cells.
- The present invention further provides another method for constructing a genetically modified semi-cloned animal library, which comprises the steps of:
- 1) infecting the AG-haESCs according to the present invention with lentiviral particles expressing Cas9 and lentiviral particles prepared with the lentiviral sgRNA library, to obtain an AG-haESC library with constant expression of the sgRNA library and Cas9;
- 2) obtaining a semi-cloned embryo library by ICAHCI with AG-haESCs in the AG-haESC library with constant expression of the sgRNA library and Cas9 as a donor for ICAHCI; and
- 3) incubating the embryos in the semi-cloned embryo library to obtain a semi-cloned animal library.
- The virus particles expressing Cas9 can be obtained by cloning the encoding gene expressing Cas9 into a lentiviral vector and then packaging the lentivirus in the prior art. The lentiviral vector expressing Cas9 is commercially available.
- The semi-cloned animal library comprises several genetically mutated semi-cloned animals. The animals may be heterozygous or biallelic mutant animals.
- Further, semi-cloned animals can be obtained by culturing the semi-cloned embryos in a suitable female organism by embryo transfer. In a preferred embodiment, the suitable female organism may be a pseudopregnant ICR female rat.
- The present invention also provides a genetically modified semi-cloned animal library, which is constructed according to the method as described above.
- The genetically modified semi-cloned animal library of the present invention can be used in genetic screening of genes at subordinate individual level.
- The semi-cloned animal library of the present invention may be a non-human mammalian library. Preferably, the semi-cloned animal library is a rodent library, such as a rabbit library, and a murine library. In a preferred embodiment, the semi-cloned animal library is a mouse library.
- The embodiments of the present invention are described below with reference to specific examples, and other advantages and effects of the present invention can be easily understood by those skilled in the art from the disclosure of the present invention. The present invention can also be implemented or practiced through additional different specific embodiments. The details in this specification may also be based on different perspectives and applications, and various modifications or changes can be made without departing from the spirit of the present invention.
- When a numerical range is given in an example, it is to be understood that both endpoints of each numerical range and any numerical value between the two endpoints are encompassed, unless the context otherwise indicates. Unless defined otherwise, all technical and scientific terms as used herein have the same meanings as those commonly understood by those skilled in the art. In addition to the specific methods, equipment and materials used in the examples, the present invention may be implemented using any of the methods, devices, and materials in the prior art that are similar or equivalent to the methods, devices, and materials described in the examples of the present invention, based on the knowledge of those skilled in the art the prior art and the disclosure of the present invention,
- Unless otherwise specified, in the experimental methods, detection methods, and preparation methods disclosed in the present invention, the conventional molecular biology, biochemistry, chromatin structure and analysis, analytical chemistry, cell culture, recombinant DNA technology and conventional techniques in related fields are adopted. These techniques are well documented in the literature.
- AG-haESCs: androgenetic haploid embryonic stem cells
- DKO-AG-haESCs: H19 DMR and IG-DMR double knockout androgenetic haploid embryonic stem cell
- 1. Experimental Materials and Methods
- 1.1. Materials and Reagents
- The cell culture medium (DMEM), fetal bovine serum (FBS), serum replacement (KSR), trypsin, Opti-MEM, DPBS, and Lipofectamine 2000 were purchased from Life Technologies Inc.; the restriction endonucleases and T4 ligase were purchased from NEB; the Taq enzyme and dNTPs were purchased from TaKaRa; the CDNA reverse transcription kit, and fluorescent quantification reagent SYBR-Green were purchased from TOYOBO; and the oligonucleotides were synthesized by Shanghai Generay Company.
- HEPES-CZB culture medium
- H-CZB Stock 98.5 ml, Hepes.2Na (sigma, CAT#H0763) or ICN 520 mg or Hepes (sigma, CAT#H4034) 476 mg, NHCO3 42 mg, CaCl2.2H2O 100×
stock 1 ml, Pyruvate 3.0 mg, andGlutamin 200× stock 0.5 ml, adjusted to pH 7.4, and filtered well. - H-CZB stock:
- CZB stock 500 ml, PVA (sigma, P8136) 50 mg, CZB stock: H2O 985 ml, NaCl (sigma, CAT#55886) 4760 mg, KCL (sigma, CAT#P5405) 360 mg, MgSO4.7H2O (sigma, CAT#M1880) 290 mg, EDTA-2Na (sigma, CAT#E6635) 40 mg, Na-Lactate (sigma, CAT#L7900) 5.3 ml, D-Glucose (sigma, CAT#G6152) 1000 mg, and KH2PO4 (sigma, CAT#P5655) 160 mg
- Activation solution: 10 mM Sr2+, 5 ng/ml Trichostatin A (TSA)
- KSOM culture medium (KSOM+AA with glucose): millipore, CAT#MR-106-D
- ESC medium:
- DMEM (millipore, CAT#SLM-220-M) 75%, 20% serum replacement KSR (Gibco, CAT#10828-028), 1,500 U/ml LIF (Millopre, CAT#ESG1107), 3M CHIR99021 (Stemgent, CAT#04-0004), and 1M PD0325901 (Stemgent, CAT#04-0006)
- Acid Tyrode solution: sigma, CAT#T1788
- CZB culture medium:
- CZB stock 99ML, CaCl2.2H2O 100×
stock 1 ml, Pyruvate 3.0 mg,Glutamin 200× stock 0.5 ml, BSA 500 mg - pX330-mCherry:
- enzymatically cleaving px330 (addgene) plasmid with Notl, and then inserting a CMV-mcherry-pA fragment amplified from pmCherry-C1 (Clontech) into the enzymatically cleaved px330 plasmid.
-
Primers for amplification: mCherry-F: ATTTGCGGCCGCATAGTAATCAATTACGGG mCherry-R: ATTTGCGGCCGCATGCAGTGAAAAAAATGC - Lentiviral sgRNA library of mice: supplied by Addgene
- viral plasmid expressing Cas9: supplied by Addgene
- Cas9 mRNA:
- obtained as described in Wang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., and Jaenisch, R. (2013). One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 153, 910-918.
- Round spermatid:
- The mouse testis was digested with collagenase IV for 20 minutes and then with trypsin for 10 minutes, and then sorted by FACS, to obtain round spermatid of mice.
- 1.2. Test Animals
- All animals were used in accordance with the procedures in the animal operation manual of Institute of Biochemistry and Cells, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences.
- H19 Δ3.8 kb KO mice (C57/B6 background, homozygous): constructed as described in (Thorvaldsen, J. L., Mann, M R., Nwoko, O., Duran, K. L., and Bartolomei, M. S. (2002). Analysis of sequence upstream of the endogenous H19 gene reveals elements both essential and dispensable for imprinting. Molecular and cellular biology 22, 2450-2462.)
- IG-DMRKO mice (C57/B6 background, heterozygous): constructed as described in (Lin, S. P., Youngson, N., Takada, S., Seitz, H., Reik, W., Paulsen, M., Cavaille, J., and Ferguson-Smith, A C. (2003). Asymmetric regulation of imprinting on the maternal and paternal chromosomes at the Dlk1-Gtl2 imprinted cluster on
mouse chromosome 12. Nature genetics 35, 97-102) - B6D2F1 (C57BL/6×DBA2) female mice: female offspring obtained after mating with female mice of C57BL/6 strain with male mice of DBA2 strain.
- Pseudopregnant ICR female mice: ICR adult female mice purchased from SLAC Laboratory Animal Co., Ltd were mated with ligated adult ICR male mice, to obtain pseudopregnant ICR female rats.
- 1.3. Establishment of AG-haESC Line
- The AG-haESC line was constructed according a reported method (Yang, H., Shi, L., Wang, B. A., Liang, D., Zhong, C., Liu, W., Nie, Y., Liu, J., Zhao, J., Gao, X., et al. (2012). Generation of genetically modified mice by oocyte injection of androgenetic haploid embryonic stem cells. Cell 149, 605-617).
- Method:
- The MII oocytes were enucleated, into which the corresponding sperm heads were injected. Mouse MII oocytes were harvested 14 hours after treatment with human chorionic gonadotropin (HCG) and then enucleated using a Piezo needle in HEPES-CZB medium containing 5 μg/ml cytochalasin B (CB). After enucleation, single sperm heads were injected into the cytoplasm of the oocytes. The reconstructed embryos were cultured in CZB medium for 1 hour and then transferred to the activation solution containing 1 mM Sr2+ for activation. After activation, all reconstructed embryos were transferred to KSOM medium containing amino acids and incubated at 37° C., and 5% CO2. The reconstructed embryos reaching the morula or blastula stage 3.5 days later were seeded in ESC medium.
- The zona pellucid of the reconstructed embryos was removed by digestion with the acid Tyrode solution. Each embryo was transferred to a 96-well plate plated with a mouse fibroblast feeder layer and cultured with ESC medium containing 20% serum replacement (KSR), 1,500 U/ml LIF, 3M CHIR99021 and 1 M PD0325901. After 4-5 days of culture, the cell clones were trypsinized and transferred to a 96-well plate plated with a fresh feeder layer. The cells were further expanded, and passaged into a 48-well plate and further into a 6-well plate, and the cells were daily maintained in a 6-well plate. To sort the haploid cells, after the embryonic stem cells were trypsinized, they were washed once with PBS (GIBCO) and then in ESC medium containing 15 μg/ml Hoechst 33342. After being placed in a water bath for 30 min, haploid cells of 1N peak were sorted by the flow cytometer BD FACS Ariall and subsequently subcultured to obtain the AG-haESC line.
- 1.4 CRISPR-Cas9-Mediated Genetic Manipulation
- Construction of CRISPR-Cas9 plasmid: The synthesized forward oligonucleotide strand and reverse oligonucleotide strand of sgRNA were annealed to obtain a double-stranded oligonucleotide strand (in the present invention, the sgRNA sequence refers to the sequence of the forward oligonucleotide strand of the sgRNA), which was then ligated to pX330-mCherry enzymatically cleaved with BbsI (New England Biolabs). The constructed corresponding plasmid was transfected into the AG-haESCs using Lipofectamine 2000 (Life Technologies) according to the instructions. 48 hours after transfection, the haploid cells with the red fluorescent protein were sorted by flow cytometry (FACSAriaII, BD Biosciences) and then plated at a low density. After 4-5 days of growth, monoclones were picked up for subsequent construction of cell lineages. Finally, cell lines with corresponding gene mutations were obtained by sequencing target genes by PCR.
- If gene knock-in was involved, a double-stranded DNA donor needed to be constructed.
- Preparation of double-stranded DNA donor:
- A sequence encoding EGFP, mCherry or ECFP was amplified and then ligated to the pMD19-T vector, to give pMD19-T-EGFP/mCherry/ECFP. Subsequently, the left and right homologous arms of the target gene were inserted into the pMD 19-T-EGFP/mCherry/ECFP vector.
- 1.5. Virus Production and Viral Infection of Double Knockout AG-haESCs (DKO-AG-haESCs)
- The viral sgRNA library of mice and the Cas9 expressing viral plasmid have been reported mice (Cong., L, Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L A., et al. (2013). Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823; and Koike-Yusa, H., Li, Y., Tan, E. P., Velasco-Herrera Mdel, C., and Yusa, K. (2014). Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. Nature biotechnology 32, 267-273, 2014). The viral sgRNA library of mice and the Cas9 expressing viral plasmid used in the present invention were provided by Addgene. To prepare the virus, HEK293T was passaged in advance into a 10 cm petri dish, 3 μg of viral plasmid (lentiviral sgRNA library or lentiviral Cas9) and 9 μg of ViraPower Lentiviral Packaging Mix (Invitrogen) were transfected into HEK293T cells by using Lipofectamine® 2000 Reagent (Invitrogen, Life Technologies). The supernatant were collected 72 hours after transfection and concentrated with Lenti-Concentin virus precipitation solution (SBI) and then stored at −80° C.
- Infection with lentiviral Cas9: A cell suspension of 108 DKO-AG-haESCs was infected for 48 hours with 8 μg/ml polybrene (Sigma) and packaged lentiviral Cas9, and then screened for 3 days with 10 μg/ml blasticidin (Sigma). The remaining resistant clone was a cell line integrated with lentiviral Cas9.
- Infection with lentiviral sgRNA library: A cell suspension of 108 DKO-AG-haESCs was infected for 48 hrs with 8 μg/ml polybrene (Sigma) and packaged lentiviral CRISPR-sgRNA library, and then screened for 2 days in a medium comprising 1 μg/ml puromycin (Invitrogen), to obtain a positive clone that is a cell line carrying lentiviral sgRNA library.
- Co-infection with lentiviral Cas9 and lentiviral sgRNA library:
- A cell line integrated with lentiviral Cas9 was prepared first, then further infected with the lentiviral sgRNA library, and then screened for 2 days in a medium comprising 1 μg/ml puromycin (Invitrogen), to obtain a positive clone that is a cell line integrated with lentiviral Cas9 and lentiviral sgRNA library.
- If the DKO-AG-haESC cell line was only infected with the lentiviral sgRNA library, then the cells did not express Cas9. At this time, transfection with the pX330-mCherry plasmid at the cellular level was needed to achieve the genome editing.
- 1.6. Bisulfite Sequencing for Methylation
- 1) Mouse DNA was packaged into beads with 15 μl of 2% LMP agarose (low melting point agarose), 460 μl of DNA digestion buffer, and then 40 μl of proteinase K were added to each sample and the sample was digested by incubation overnight at 50° C.
- 2) After 3 washes with TE, the beads were reacted with a bisulfate solution and incubated at 50° C. for 4-8 hours.
- 3) Nested PCR was performed using the beads as a template, and the PCR product was recovered and then ligated to the PMD19-T vector, followed by transformation and plating.
- 4) 10 colonies were picked from each sample for sequencing.
- If the EZ DNA methylation Gold kit (ZYMO Research) was used, an appropriate amount of DNA was prepared, and the following procedures were operated according to the steps of use of the kit. The resulting product recovered with the kit was used as a template for PCR, the product was recovered and then ligated to the PMD19-T vector, followed by transformation and plating. 10 colonies were picked from the plate for sequencing.
- 1.7. Fluorescent Quantitative PCR
- Total RNA was extracted from the cells or organs with Trizol reagent (Invitrogen) and then 1 μg of total RNA was reversely transcripted into cDNA using the First Strand cDNA Synthesis kit (TOYOBO). Real-time fluorescent quantitative PCR reactions were performed on a Bio-Rad CFX96 instrument using SYBR Green Realtime PCR Master Mix (TOYOBO), with 3 replicates for each set of samples. All the gene expression levels were detected with the expression level of housekeeping gene Gapdh as an internal reference.
- 1.8. Cobra Assay
- 1) 100 ng of sample DNA was taken and enzymatically cleaved with TaqI restriction endonuclease (Fementas) (T/CGA) for 15 min
-
- 2) Agarose gel electrophoresis was performed.
- 1.9. Construction of Semi-Cloned Mice by ICAHCI, ROSI and Embryo Transfer
- Intracytoplasmic AG-haESCs injection (ICAHCI):
- To obtain semi-cloned (SC) embryos, AG-haESCs were treated for 8 hrs with a medium containing 0.05 μg/ml colchicine to synchronize the cells to M phase and then intracytoplasmically injected into the oocytes. The digested AG-haESCs were washed 3 times with HEPES-CZB medium and then re-suspended in 3% (w/v) polyvinylpyrrolidone (PVP) in HEPES-CZB medium. Nuclei of AG-haESCs in M phase were injected into MII oocytes under a Piezo microscope. The reconstructed embryos were cultured in CZB medium for 1 hour and then activated with a CB-free medium for 5-6 hours. After activation, all the reconstructed embryos were cultured in KSOM medium at 37° C., and 5% CO2. ICAHCI embryos reached 2-cell embryo after being cultured in the KSOM medium for 24 hours.
- ROSI (round spermatid injection):
- The operation followed a reported method (Kishigami, S., Wakayama, S., Nguyen, V. T., and Wakayama, T. (2004). Similar time restriction for intracytoplasmic sperm injection and round spermatid injection into activated oocytes for efficient offspring production. Biology of reproduction 70, 1863-1869).
- Every 15-20 2-cell embryos obtained by ICAHCI or ROSI were transferred into each uterus of pseudopregnant ICR mice at 0.5 dpc (0.5 day post-mating). The female mice experienced caesarean section or natural birth after 19.5 days of pregnancy. Caesarean section was done for reconstructed embryos obtained with WT AG-haESCs or single DMR knockout AG-haESCs, and expired fetuses were quickly peeled off from the female's uterus. For embryos obtained by ROSI or with DKO-AG-haECs, females after 19.5 days of pregnancy experienced natural birth. After removing the fluid from the born mice, the mice were placed in an oxygen incubator, and survived mice were subsequently nourished by the surrogate females.
- 1.10. RNA-Seq and Gene Expression Analysis
- The RNA-seq library of total RNA was established according to Illumina's official TreSeq RNA Sample Prep v2 Guide. After establishment, deep sequencing was performed on the IlluminaHiSeq 2000 instrument available from the Computational Biology Center of the Institute of Computing Biology, Chinese Academy of Sciences-Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. 6 samples, comprising 2 WT AG-haESCs, H19Δ
DMR -IGΔDMR -AGH, H19ΔDMR -IGΔDMR -AGH-OG3, IGΔDMR -H19ΔDMR -AGH and round spermatid were subjected to subsequent analysis. - The algorithm for gene expression level was RPKM, specifically as described in (Yang, L., Duff, M. O., Graveley, B. R., Carmichael, G. G., and Chen, L. L. (2011). Genomewide characterization of non-polyadenylated RNAs.
Genome biology 12, R16). - The p-value of differentially expressed genes was calculated using the waldscore method (Yang et al., Genome boil 2011) in which abs (waldscore) was set to be >1.96 (that is, p-value<0.05), and then the differentially expressed genes were screened.
- 1.11. RRBS (Reduced Representation Bisulfite Sequencing)
- The RRBS library was established according to Illumina's official protocol, and then sequenced on the IlluminaHiSeq 2000 instrument (Gu, H., Smith, Z. D., Bock, C., Boyle, P., Gnirke, A., and Meissner, A. (2011). Preparation of reduced representation bisulfite sequencing libraries for genome-scale DNA methylation profiling.
Nature protocols 6, 468-481.). All sequencing reads were aligned with the mouse genome. - 1.12. Genotyping Methods
- The extracted genomic DNA was amplified by PCR using corresponding primers, and the PCR product was further subjected to agarose gel electrophoresis.
- Construction of Semi-Cloned Mice Based on H19 DMR Single Knockout AG-haESC Line
- A. Construction of AG-haESC Line:
- Source of spermatids: H19 Δ3.8 kb KO mice (C57/B6 background, homozygous);
- Source of oocytes: B6D2F1 (C57BL/6×DBA2) female mice
- The haploid sperm heads of H19 Δ3.8 kb mice were injected into enucleated oocytes (
FIG. 1A ) following the method as described in Section 1.3, to obtain reconstructed blastocysts, with which AG-haESC cell lines were constructed. Three haploid cell lines were established from 250 reconstructed blastocysts (which were designated as H19ΔDMR -AGH-1, H19ΔDMR -AGU-2, H19ΔDMR -AGU-3) (FIGS. 1B-1D ). - B. Construction of Semi-Cloned Mice:
- Following the method as described in Section 1.9, H19-AGH cells were used as a donor for ICAHCI, and 1443 2-cell embryos reconstructed with these 3 cell lines were transferred into the pseudopregnant female mice. Finally, 86 healthy, viable semi-cloned mice and 39 growth-arrested mice were obtained by caesarean section of the female mice on day 19.5 after pregnancy (
FIG. 1E , Table 1). The birth rate in normal half-cloned mice is about 5.9%; however, about 2.7% of the semi-cloned mice developed from the embryos constructed with H19ΔDMR -AGH still have abnormal growth. - Semi-cloned mice were constructed with wild-type AG-haESCs as a donor for ICAHCI. The birth rate of normal semi-cloned mice is about 0.7-1.8%.
- C. Detection of Gtl2 Expression
- Fluorescent quantitative PCR was used to detect whether aberrant high expression of Gtl2 was also present in the major organs of H19Δ
DMR -AGH-derived growth-arrested mice, following the method as described in Section 1.7. -
Primer sequences for fluorescent quantitative PCR: Gtl2-F: TTGCACATTTCCTGTGGGAC Gtl2-R: AAGCACCATGAGCCACTAGG - The experimental results show that Gtl2 overexpression occurs in most of the organs tested in growth-arrested semi-cloned mice compared to normal mice (Fig. S1E).
- D. Methylation Analysis
- Experimental Methods: The analysis was carried out following the methods as described in Sections 1.6 and 1.8.
-
Primers used: IG DMR-BS-OF: TTAAGGTATTTTTTATTGATAAAATAATGTAGTTT IGD MR-BS-OR: CCTACTCTATAATACCCTATATAATTATACCATAA IG DMR-BS-IF: TTAGGAGTTAAGGAAAAGAAAGAAATAGTATAGT IG DMR-BS-IR: TATACACAAAAATATATCTATATAACACCATACAA - The results of methylation analysis show that the growth-arrested semi-cloned mice show obvious hypomethylation in the IG-DMR region of the differential methylation sites in the Dlk1-Gtl2 imprinted cluster (Figs. S1F-G). Interestingly, a more severe loss of IG-DMR methylation imprinting occurred in the later generation of H19Δ
DMR -AGH (H19ΔDMR -AGU-1, p16) compared to with its earlier generation (H19ΔDMR -AGH-1, p7), resulting in a significantly increased rate of growth arrested mice (Fig. S1H, Table S1). This indicates that the abnormal expression of Gtl2 may be another important factor leading to the failure in development of the semi-cloned mice obtained with H19ΔDMR -AGH cells. - Construction of Semi-Cloned Mice Based on H19 DMR and IG-DMR Double Knockout AG-haESC Line
- A. Construction of H19 DMR and IG-DMR Double Knockout AG-haESC Line:
- The construction was carried out following the method as described in Section 1.4.
- 2 sgRNAs were designed according to the sequence between Dlk1 and Gtl2 which had a 4.15 kb IG-DMR knocked out (designated as IG-DMR-sgRNA1 and IG-DMR-sgRNA2) (
FIG. 1F ). -
IG-DMR-sgRNA1 sequence: (SEQ ID NO: 1) CGTACAGAGCTCCATGGCAC IG-DMR-sgRNA2 sequence: (SEQ ID NO: 2) CTGCTTAGAGGTACTACGCT - The plasmids pX330-mCherry expressing Cas9 and IG-DMR-sgRNAs were constructed and transfected into the H19Δ
DMR -AGH cells, to finally obtain 71 AG-haESC lines. The sequencing of the PCR product of the target gene (IG-DMR deletion check-F: TGTGCAGCAGCAAAGCTAAG; IG-DMR deletion check-R: ATACGATACGGCAACCAACG) found that the IG-DMR were successfully knocked out in 58 cell lines (designated as H19ΔDMR -IGΔDMR -AGH-1 through H19ΔDMR -IGΔDMR -AGH-58) (FIGS. 1G , S2A and S2B). Off-target analysis of H19ΔDMR -IGΔDMR -AGH-2 shows that no mutations occur to a total of 22 potential off-target sites (Table S2), where these sites are predicted by genome-wide searching by using software reported previously (Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013). DNA targeting specificity of RNA-guided Cas9 nucleases. Nature biotechnology 31, 827-832). - B. Construction of Semi-Cloned Mice:
- Following the method as described in Section 1.9, H19Δ
DMR -IGΔDMR -AGH cells were used as a donor for ICAHCI to construct semi-cloned mice. The results show that 22.3% of the semi-cloned embryos can well developed (FIG. 1H ,Fig. S2C , Table 1, Table S1), which is similar to the ROSI birth rate reported by our laboratory (Table 1) or other laboratories (Kishigami, S., Wakayama, S., Nguyen, V. T., and Wakayama, T. (2004). Similar time restriction for intracytoplasmic sperm injection and round spermatid injection into activated oocytes for efficient offspring production. Biology of reproduction 70, 1863-1869.). Furthermore, compared with the semi-cloned mice obtained with wild type AG-haESCs and H19ΔDMR -IGΔDMR -AGH by ICAHCI that require caesarean section, after the embryos reconstructed with H19ΔDMR -IGΔDMR -AGH-2 is transferred to pseudopregnant female mice, the pseudopregnant female mice can carry out natural birth, and the born semi-cloned mice all survive healthy. The data suggests that H19ΔDMR -IGΔDMR -AGH cells obtain characteristics resembling a round spermatid successfully by knocking out IG-DMR, from which semi-cloned mice can be produced efficiently. - Construction of Semi-Cloned Mice Based on IG-DMR Single Knockout AG-haESC Line
- A. Construction of AG-haESC Line:
- Source of spermatids: IG-DMR KO mice;
- Source of oocytes: B6D2F1 (C57BL/6×DBA2) female mice
- The haploid sperm heads of IG-DMR KO mice were injected into enucleated oocytes following the method as described in Section 1.3, to obtain reconstructed blastocysts, with which AG-haESC cell lines were constructed. Among the 8 haploid cell lines established, 2 cell lines carried IG-DMR knockout (designated as IGΔ
DMR -AGH-1 and IGΔDMR -AGH-2) - B. Construction of Semi-Cloned Mice:
- Following the method as described in Section 1.9, IGΔ
DMR -AGH cells were used as a donor for ICAHC to construct semi-cloned mice. It is found that the IGΔDMR -AGH cells are not donors effective in the production of semi-cloned mice (Table 1, Table S1), with which it is difficult to obtain healthy normal SC mice (where only 4 normal SC mice are obtained from 499 transferred embryos) (FIGS. 2A and S2E). Moreover, most of the mice are growth arrested. - C. Methylation Analysis
- Experimental Methods: The analysis was carried out following the methods as described in Sections 1.6 and 1.8.
-
Primers used: H19 DMR-BS-OF: 5′ GAGTATTTAGGAGGTATAAGAATT 3′H19 DMR-BS-OR: 5′ ATCAAAAACTAACATAAACCCCT 3′H19 DMR-BS-IF: 5′ GTAAGGAGATTATGTTTATTTTTGG 3′H19 DMR-BS-IR: 5′ CCTCATTAATCCCATAACTAT 3′ - The result show that the H19 DMR of IGΔ
DMR -AGH cell line suffers erased methylation, and complete loss of methylation occurs in the growth-arrested mice (FIGS. 2B , S2F, and S2G). - Construction of Semi-Cloned Mice Based on H19 DMR and IG-DMR Double Knockout AG-haESC Line
- A. Construction of H19 DMR and IG-DMR Double Knockout AG-haESC Line:
- The construction was carried out following the method as described in Section 1.4.
-
H19 Δ3.8kb DMR KO sgRNA sequence: H19-3.8K sgRNA-1: (SEQ ID NO: 3) CATGAACTCAGAAGAGACTG H19-3.8K sgRNA-2: (SEQ ID NO: 4) AGGTGAGAACCACTGCTGAG - The H19 Δ3.8 kb DMR were knocked out from the IGDMR-AGH cell line obtained in the above example by the CRISPR-Cas9 method (see Thorvaldsen, J. L., Mann, M. R., Nwoko, O., Duran, K. L., and Bartolomei, M. S. (2002). Analysis of sequence upstream of the endogenous H19 gene reveals elements both essential and dispensable for imprinting. Molecular and cellular biology 22, 2450-2462), and 13 DKO-AG-haESC cell lines were successfully obtained (designated as IGΔ
DMR -H19ΔDMR -AGH-1 through IGΔDMR -H19ΔDMR -AGH-13) (FIGS. 2C and S2H, and Table S2). - B. Construction of Semi-Cloned Mice:
- Following the method as described in Section 1.9, 2 cell lines above were used as a donor for ICAHCI to construct semi-cloned mice. The results show that the 2 cell lines have the similar ability to produce health SC mice as the H19Δ
DMR -IGΔDMR -AGH cells (Figs. S2I and 2J, and Table 1, Table S1). - Construction of Semi-Cloned Mice Based on H19-DMR and IG-DMR Double Knockout AG-haESC Line
- A. Construction of H19-DMR and IG-DMR Double Knockout AG-haESC Line:
- Initial cells: 21st-generation AGH-OG-3 cells of WT-AG-haESC cell line AGH-OG-3
- It has been reported that the 22nd generation of this cell line has substantially lost the ability to produce healthy, semi-cloned mice (Yang, H., Shi, L., Wang, B. A., Liang, D., Zhong, C., Liu, W., Nie, Y., Liu, J., Zhao, J., Gao, X., et al. (2012). Generation of genetically modified mice by oocyte injection of androgenetic haploid embryonic stem cells. Cell 149, 605-617).
- The oligo of sgRNA were annealed and then the sgRNAs of H19 and IG-DMR were respectively ligated to the BbsI digested px330-mCherry plasmid and transformed. Plasmid was extracted from the bacterial suspension sequenced to be correct for subsequent transfection.
- The 21st generation of the AGH-OG-3 cell line was transformed with the plasmid obtained above.
- 12 H19 and Gtl2 DMR double knockout AG-haESC cell lines (designated as H19Δ
DMR -IGΔDMR -AGH-OG3-1 through H19ΔDMR -IGΔDMR -AGH-OG3-12) were finally obtained (FIGS. 2D and S3A and Table S2). - B. Construction of Semi-Cloned Mice:
- Following the method as described in Section 1.9, H19Δ
DMR -IGΔDMR -AGH-OG3 cells were used as a donor for ICAHCI to construct semi-cloned mice. Surprisingly, by injecting 2 of these cell lines into MII oocytes, about 17% of semi-cloned embryos were able to develop fully (Fig. S3B, S3C, Table 1, and Table S1). This shows that WT-AG-haESCs, which had previously completely lost the ability to produce SC mice, were able to regain characteristics resembling a round spermatid after knockdown of H19-DMR and IG-DMR. - Genotyping of SC Mice Obtained with 3 DKO-AG-haESC Lines
- Genotyping method: The method as described in Section 1.12 was used.
-
H19-DMR deletion check-F2: GTGGTTAGTTCTATATGGGG H19-DMR deletion check-R2: TCTTACAGTCTGGTCTTGGT IG-DMR deletion check-F: TGTGCAGCAGCAAAGCTAAG IG-DMR deletion check-R: ATACGATACGGCAACCAACG - Three H19-DMR and IG-DMR double-knockout AG-haESC cell lines were constructed by using the three methods described in the foregoing Examples 2, 4 and 5, and a total of 402 SC mice were obtained. A mouse birth rate of 20.2% was achieved with the transferred embryos. These DKO-AG-haESC derived SC mice are able to grow to adulthood and are capable of producing offspring. Genotyping of 33 neonatal mouse offspring in 7 litters find that 13 animals carry H19-DMR knockout and 11 animals are WT (
FIG. 2E ). 6 out of the other 9 mice have IG-DMR knockout and 3 have H19 and Gtl2 DMR double knockouts. The 9 mice died shortly after birth, consistent with the previously reported lethal phenotype of the maternally inherited IG-DMR before or after birth (Lin, S. P., Youngson, N., Takada, S., Seitz, H., Reik, W., Paulsen, M., Cavaille, J., and Ferguson-Smith, A C. (2003). Asymmetric regulation of imprinting on the maternal and paternal chromosomes at the Dlk1-Gtl2 imprinted cluster onmouse chromosome 12. Nature genetics 35, 97-102). - Detection of Gene Expression and Methylation Analysis of AG-haESCs
- RNA-seq and gene expression analysis were performed following the methods described previously in Sections 1.10 and 1.7.
- Reagent: SYBR-Green (TOYOBO)
-
Primers for Q-PCR: Gapdh-F: CACTCTTCCACCTTCGATGC Gapdh-R: CTCTTGCTCAGTGTCCTTGC Igf2-F: CTAAGACTTGGATCCCAGAACC Igf2-R: GTTCTTCTCCTTGGGTTCTTTC Gtl2-F: TTGCACATTTCCTGTGGGAC Gtl2-R: AAGCACCATGAGCCACTAGG Dlk-F ACTTGCGTGGACCTGGAGAA Dlk-R: CTGTTGGTTGCGGCTACGAT H19-F: CATGTCTGGGCCTTTGAA H19-R: TTGGCTCCAGGATGATGT - Genome-wide methylation level analysis was performed following the method as described in Section 1.11.
- The results of Q-PCR showed that the expression of H19 and Gtl2 is down-regulated while the expression of Igf2 and Dlk1 is up-regulated in DKO-AG-haESCs (
Fig. S3D ). The gene expression profiles of DKO-AG-haESCs, normal AG-haESCs and round spermatids were compared. Clustering data based on RNA-seq reveals that the expression profile of DKO-AG-haESCs is highly similar to that of WT-AG-haESCs, but greatly different from that of round spermatids (FIGS. 2F , S3E). Further analysis of the expression profiles of imprinted genes in DKO-AG-haESCs and WT-AG-haESCs revealed that all imprinted genes in DKO-AG-haESCs and WT-AG-haESCs have extremely similar expression levels (FIG. 2G ). In order to further evaluate the epigenetics, reduced representation bisulfate sequencing (RRBS) was performed to detect the genome-wide methylation level. As shown inFIGS. 2H , S3F, and S3G, knockouts of H19 and Gtl2 DMRs do not alter the methylation levels in the promoter regions of all the genes and imprinted genes detected. Taken together, the results show that H19 and Gtl2 DMRs are two major impairments for AG-haESCs in obtaining characteristics resembling spherical spermatid. - Production of Semi-Cloned Mice with DKO-AG-haESCs Carrying Multiple Genetic Modifications
- A. Construction of DKO-AG-haESCs Carrying Multiple Genetic Modifications:
- The construction was carried out following the method as described in Section 1.4.
- Initial cells: DKO-AG-haESCs. Knockouts of the TET family of genes employed the DKO-AG-haESCs prepared in Example 4, and knockouts of the p53 family of genes employed the DKO-AG-haESCs prepared in Example 2.
- Target mutations: mutations of Tet1, Tet2, Tet3, and p53 family
- Construction procedure:
- Construction procedure of Tet-TKO-DAH:
- sgRNAs of Tet1, Tet2, and Tet3 were annealed respectively, and ligated to a BbsI digested px330-mCherry plasmid respectively, and positive plasmids in which sgRNAs were ligated were picked up by sequencing.
-
Tet1 sgRNA sequence: (SEQ ID NO: 5) GGCTGCTGTCAGGGAGCTCA Tet2 sgRNA sequence: (SEQ ID NO: 6) GAAAGTGCCAACAGATATCC Tet3 sgRNA sequence: (SEQ ID NO: 7) AAGGAGGGGAAGAGTTCTCG - The plasmids expressing the sgRNAs of Tet1, Tet2, and Tet3 were co-transformed into the DKO-AG-haESC cell line. mCherry positive cells were sorted, and plated in a Petri dish. After 5 days of growth, the clones were picked and passaged for amplification. The established cell line was identified for the Tet1, Tet2, and Tet3 mutations by sequencing the PCR product.
-
Primers for sequencing: Tet1 check-F: GCCCCTGTTGTCTTATACGTT Tet1 check-R: CATTCGCCTCAGGACCAC Tet2 check-F: CCGCCACAAGAAAATATGTCC Tet2 check-R: AGCTAACTCTGGCAAACACC Tet3 check-F: CAGAGTGGCCTCAGTTTCCC Tet3 check-R: ACAACTTTTACCCAGGAGTCACAC - Construction procedure of p53-TKO-DAH:
- sgRNAs of p53, p63, and p73 were annealed respectively, and ligated to a BbsI digested px330-mCherry plasmid respectively, and positive plasmids in which sgRNAs were ligated were picked up by sequencing.
-
p53 sgRNA sequence: (SEQ ID NO: 8) CACCTGGGCTTCCTGCAGTC p63 sgRNA sequence: (SEQ ID NO: 9) TGGGCCCGGGTAATCTGTGT p73 sgRNA sequence: (SEQ ID NO: 10) TGTCGATAGGAGTCAACCAA - The plasmids expressing the sgRNAs of p53, p63, and p73 were co-transformed into the DKO-AG-haESCs cell line. mCherry positive cells were sorted, and plated in a Petri dish. After 5 days of growth, the clones were picked and passaged for amplification. The established cell line was identified for the p53, p63, and p73 mutations by sequencing the PCR product.
-
P53 check-F: CCCCTGTCATCTTTTGTCCCT P53 check-R: AAGAGAGTTCCACGTCCCCTG P63 check-F: CACACCAAATAATGCCAATT P63 check-R: CAGACTCTCTTACCGTCCAG P73 check-F: GACCCACTTCTAAACCTGCC P73 check-R: CCATACCTCCTGTGCTCCTG - B. Construction of Semi-Cloned Mice:
- Following the method as described in Section 1.9, the cells constructed above were used as a donor for ICAHCI to construct semi-cloned mice.
- C. Results
- In this example, Tet1, Tet2 and Tet3 were mutated in DKO-AG-haESCs by CRISPR-Cas9 method. The plasmids constructed to express Cas9 and 3 sgRNAs of Tet1, 2, and 3 (
FIG. 3A ) (see Wang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., and Jaenisch, R. (2013). One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 153, 910-918) were transformed into DKO-AG-haESCs. 56 DKO-AG-haESC lines were finally established. The sequencing of the PCR products of the Tet1, 2, and 3 gene revealed that triple gene mutations occur in 18 cell lines (designated as Tet-TKO-DAH-1 through Tet-TKO-DAH-18) (FIGS. 3B-D and S4A). ICAHCI results of 4 of the cell lines indicated that SC mice with Tet1, 2 and 3 mutations can be obtained with corresponding rate (FIGS. 3E and S4B, Table 1 and Table S3). Corresponding SC mice can also be obtained with DKO-AG-haESCs with mutant p53 family of genes by ICAHCI (Figs. S4D , S4E, Table 1 and Table S3). These results show that WT-AG-haESCs are failed to produce viable SC mice after in vitro genetic manipulation, but DKO-AG-haESCs are still able to efficiently and stably produce semi-cloned mice after gene editing. - Gene Editing of DKO-AG-haESCs and Production of Semi-Cloned Mice Therewith
- A. Construction of Genetically Edited DKO-AG-haESC Cell Line
- Initial cells: DKO-AG-haESCs (prepared in Example 4)
- Construction procedure:
- Construction procedure of Tet1&3-KI-DAH:
- sgRNAs of Tet1, and Tet3 were annealed and ligated to a BbsI digested px330-mCherry plasmid respectively, and positive plasmids in which sgRNAs were ligated were picked up by sequencing. For the preparation of Tet1-EGFP and Tet3-ECFP donors, pEGFP-N1 plasmid and pECFP-N1 plasmid were respectively used as a template (primers: P2A-fluorescence F: GCCACGAAGCAAGCAGGAGATGTTGAAGAAAACCCCGGGCCTGTGAGCAAGGGCG AGGAG
- P2A-fluorescence R: CTTGTACAGCTCGTCCATG), a sequence encoding EGFP or ECFP was amplified, and then correspondingly ligated to a multiclonal site on a pMD19-T vector, to obtain a pMD19-T-EGFP/ECFP vector. Subsequently, the left and right homologous arms of the gene of interest were respectively inserted into two sides of the EGFP or ECFP gene in the pMD19-T-EGFP/ECFP vector.
- Sequences of homologous arms:
- TET1LA (left homologous arm): (SEQ ID NO: 11)
- TET1 RA (right homologous arm): (SEQ ID NO: 12)
- TET3 LA (left homologous arm): (SEQ ID NO: 13)
- TET3 RA (right homologous arm): (SEQ ID NO: 14)
- The 4 plasmids, comprising plasmids carrying Tet1 and Tet3 sgRNA, and Tet1-EGFP and Tet3-ECFP donors were co-transfected into the DKO-AG-haESCs cell line. mCherry positive cells were sorted, and plated in a Petri dish. After 5 days of growth, the clones were picked and passaged for amplification. The established cell line was identified for the Tet1-EGFP and Tet3-ECFP knockins by PCR. The double knock-in cells were designated as Tet1&3-KI-DAH.
-
Primers for identification by PCR: Tet1 LA-F: TTTGTGTCTATGAACTACCAGTGAG Tet1 LA-F: CAGGCCCGGGGTTTTCTTC Tet1 RA-F: CAACGAGAAGCGCGATCACA Tet1 RA-F: TTTTGACTGATCCCAATTTGCCT Tet3 LA-F: TGTTCACTGGTGAAGGCCAG Tet3 LA-F: GAACAGCTCCTCGCCCTTG Tet3 LA-F: TGAGCAAAGACCCCAACGAG Tet3 RA-R: ATCGACAAACTTTGGGGCGA - Construction procedure of Tet-TKI-DAH:
- sgRNA of Tet2 was annealed and ligated to a BbsI digested px330-mCherry plasmid, and a positive plasmid in which sgRNA was ligated was picked up by sequencing.
- For the preparation of Tet2-mCherry donor, by using pmCherry-N1 as a template, and P2A-fluorescence F: GCCACGAAGCAAGCAGGAGATGTTGAAGAAAACCCCGGGCCTGTGAGCAAGGGCG AGGAG and P2A-fluorescence R: CTTGTACAGCTCGTCCATG as primers, a sequence encoding mCherry was amplified and then ligated to a pMD19-T carrier. Subsequently, the left and right homologous arms of the gene of interest were respectively inserted into two sides of the mCherry sequence in the pMD19-T-mCherry vector.
- TET2 LA (left homologous arm): (SEQ ID NO: 15)
- TET2 RA (right homologous arm): (SEQ ID NO: 16)
- The 2 plasmids, comprising the plasmid carrying Tet2 sgRNA and the Tet2-mCherry donor were co-transfected into the Tet1&3-KI-DAH cell line. mCherry positive cells were sorted, and plated in a Petri dish. After 5 days of growth, the clones were picked and passaged for amplification. The established cell line was identified for the Tet2-mCherry knock-in by PCR. The positive cell clone was the Tet-TKI-DAH cell line.
-
Primers for identification: Tet2 LA-F: CACACCCTTCACCAACAGACG Tet2 LA-R: ATCTCGAACTCGTGGCCGTT Tet2 RA-F: AAGACCACCTACAAGGCCAAG Tet2 RA-R: GGTAGGCAAAGTGCTTTTCTAAGAC - B. Construction of Semi-Cloned Mice:
- Following the method as described in Section 1.9, the cells constructed above were used as a donor for ICAHCI to construct semi-cloned mice.
- C. Results
- In this example, DKO-AG-haESCs were obtained in which endogenous Tet1, Tet2 and Tet3 were knocked in different fluorescent reporter groups. First, DKO-AG-haESCs were transfected with a plasmid co-expressing Cas9 and Tet1 and Tet3 sgRNAs (
FIG. 3A ) and a double stranded DNA donor vector having EGFP and ECFP reporter groups fused respectively to the last terminator of Tet1 and Tet3 (FIGS. 3H and S5A). A total of 150 DKO-AG-haESC cell lines were obtained, with 10 Tet1-EGFP knock-in and 7 Tet3-ECFP knock-in cell lines (Figs. S5B and S5C). One of the cell lines carrying both Tet1-EGFP and 7 Tet3-ECFP knock-ins was designated as Tet1 & 3-KI-DAH-1 (Figs. S5D and S5E). ICAHCI results showed that DKO-AG-haESCs carrying Tet1-EGFP and Tet3-ECFP knock-ins have similar semi-cloned mice production capability to WT DKO-AG-haESCs (Figs. S5F and S5G, Table 1 and Table S3). Next, the plasmid expressing Cas9 and Tet2 sgRNA and the double-stranded DNA donor vector having the mCherry reporter group fused to the last terminator of the Tet2 gene were transfected into the Tet1 & 3-KI-DAH-1 cell line (FIGS. 3A and 3H ). Out of the established 130 cell lines, 8 red-KFP knock-in haploid cell lines were identified (designated as Tet-TKI-DAH-1 through Tet-TKI-DAH-8) (FIGS. 31 and S5H). Finally, the developmental potential of the Tet-TKI-DAH cell line was verified by ICAHCI. Consistently, Tet-TKI-DAH was able to efficiently produce viable semi-cloned mice by injection into oocytes (Figs. S5S , S5J, Table 1, and Table S3). Taken together, these results indicate that it is a possible route to produce SC mice having corresponding genetic characteristics by ICAHCI after multi-gene genetic manipulation of DKO-AG-haESCs. - Large-Scale Production of Heterozygous Mutant SC Mice with DKO-AG-haESCs Carrying sgRNA Library
- A. Construction of DKO-AG-haESCs Carrying sgRNA Library
- Initial cells: IGΔ
DMR -H19ΔDMR -AGH-1 - Following the method as described in Section 1.5, the virus was prepared and DKO-AG-haESCs were infected with a genome-wide lentiviral sgRNA library, and then transfected with a pX330-mCherry plasmid expressing Cas9, to finally construct DKO-AG-haESCs carrying the sgRNA library.
- B. Construction of Semi-Cloned Mice:
- Following the method as described in Section 1.9, semi-cloned mice were constructed using the previously constructed cells as a donor for ICAHCI.
- Detection of sgRNAs Carried in Semi-Cloned Mice:
- The sgRNAs were detected by PCR amplification using specific primers, and then the PCR product was subjected to agar gel electrophoresis to observe the presence of a strip.
-
Lenti-sg-F: GTTACTCGAGCCAAGGTCGG Lenti-sg-R: GACTCGGTGCCACTTTTTCA - Detection of Allelic Mutation:
- According to the sgRNA sequencing, the corresponding gene inserted was identified, and then the upstream and downstream primers were designed by the conventional method in the vicinity of the target gene sgRNA, followed by PCR and sequencing.
- C. Results
- At present, the genome-wide sgRNA library has been successfully established and used in the loss-of-function genetic screening in human and mouse cells (Koike-Yusa, H., Li, Y., Tan, E. P., Velasco-Herrera Mdel, C., and Yusa, K. (2014). Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. Nature biotechnology 32, 267-273). This experiment demonstrates that DKO-AG-haESCs are capable of carrying the sgRNA library and that a large number of mutant mouse models can be obtained simply by a one-step method by ICAHCI (
FIG. 4A ) (this method is known as Lenti-sgRNA+pX330). In this test, a newly established and more definite mouse lentiviral library was used. This library had 87,897 sgRNAs designed for the genes of 19,150 encoded proteins in mice. 1.0×107 haploid cell line IGΔDMR -H19ΔDMR -AGH-1 enriched by FACS were infected with the genome-wide lentiviral sgRNA library. After 2 days, these infected cells were treated with puromycin for 7 days, followed by transfection with the pX330-mCherry plasmid expressing Cas9. Haploid cells expressing mCherry indicated the successful transfection and expression of Cas9, which were then used in ICAHCI experiments following FACS enrichment (FIG. 4B ). To detect whether the haploid gene is induced to be mutated by CRISPR-Cas9, 7 haploid cell clones were randomly selected. All of the detected cell clones carried one sgRNA, which was also found to be mutated by DNA sequencing, indicating that gene mutations can be successfully induced in haploid cells by CRISPR-Cas9. - 114 semi-cloned mice were obtained by three independent ICAHCI experiments (
FIG. 4E and Table 2), of which 82 carried one sgRNA (FIG. 4F ). Sequencing of the PCR products of sgRNA revealed that 43 SC mice harbored one allelic mutation of the gene of interest, 39 of which carried insertions or knockouts mutation (indel) that result in frameshift, leading to the loss of function of one allele (FIG. 4G ). Interestingly, all the mutations were of the same genotype, indicating that gene mutations are realized in haploid cells after the transient expression of Cas9. Although the remaining 39 mice carried one sgRNA, no DNA cleavage was shown at the site needed to be mutated. This rate was consistent with that previously observed in human cells (Zhou, Y, Zhu, S., Cai, C., Yuan, P., Li, C., Huang, Y., and Wei, W. (2014). High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells. Nature 509, 487-491) or mouse embryos (Wu, Y., Liang, D., Wang, Y., Bai, M., Tang, W., Bao, S., Yan, Z., Li, D., and Li, J. (2013). Correction of a genetic disease in mouse via use of CRISPR-Cas9. Cell Stem Cell 13, 659-662). This data demonstrates that the introduction of genetic mutations into SC mice can be achieved by ICAHCI of DKO-AG-haESCs harboring the sgRNA library that are transiently transfected to express Cas9, to finally obtain a large number of heterozygous mutant mice in one step. - Production of Mice Harboring sgRNA-Mediated Biallelic Mutations with DKO-AG-haESCs in One Step
- A. Construction of sgRNA-Bearing Haploid Cells
- Initial cells: IGΔ
DMR -H19ΔDMR -AGH-1 - DKO-AG-haESCs were infected with the lentiviral CRISPR-sgRNA library following the method as described in Section 1.5, to obtain a cell line carrying the lentiviral sgRNA library.
- B. Construction of Semi-Cloned Mice:
- The nuclei of the haploid cells carrying sgRNA were injected into mature oocytes by ICAHCI, followed by intracytoplasmic injection of Cas9 mRNA into the reconstructed oocyte (where this protocol was known as Lenti-sgRNA+Cas9 injection). Semi-cloned mice were then constructed by embryo transfer.
- sgRNA detection in semi-cloned mice: The detection was carried out following the method as described in Example 9.
- Detection of allelic mutation: The detection was carried out following the method as described in Example 9. In addition, the PCR product of the target gene was ligated into the pMD19-T vector, and then the clones were picked up and sequenced.
- C. Results
- In this experiment, haploid cells carrying sgRNA were injected into mature oocytes by ICAHCI and then Cas9 was injected into the reconstructed oocytes (where this protocol was known as Lenti-sgRNA+Cas9 injection). A total of 45 SC mice carrying one sgRNA were born, of which 22 had genetic mutations (Table 2). Sequencing of the PCR product of the gene of interest revealed that 10 mice had only a monoallelic modification, and other 12 mice were biallelic mutant (which is 23.5% of all born SC mice). Sequencing by TA cloning of the 7 biallelic mutant SC mice revealed that approximately 63% of the clones carried the insertion or deletion mutations (Table S4).
- Production of Mice Harboring sgRNA-Mediated Biallelic Mutations with DKO-AG-haESCs in One Step
- A. The sgRNA-bearing haploid cells were constructed following the method as described in Example 10A and the pX330-mCherry plasmid was then transiently transfected into the sgRNA-bearing haploid cells.
- B. Construction of Semi-Cloned Mice:
- The nuclei of the haploid cells obtained in A were injected into oocytes by ICAHCI, followed by intracytoplasmic injection of Cas9 mRNA. Semi-cloned mice were then constructed by embryo transfer.
- sgRNA detection in semi-cloned mice: The detection was carried out following the method as described in Example 9.
- Detection of allelic mutation: The detection was carried out following the method as described in Example 11.
- C. Results
- In this experiment, the pX330-mCheny plasmid was transiently transfected into the sgRNA-bearing haploid cells, and then the cells were injected into oocytes, followed by injection of Cas9 mRNA (Fig. S6A and S6B) (where this protocol was known as Lenti-sgRNA+pX330+Cas9 injection). A total of 27 SC mice carrying one sgRNA were obtained. 22 mice carried genetic mutations (Figs. S6C and S6D and Table 2), in which 13 of the mutant mice carried biallelic mutations (Fig. S6E) (which was 41.9% of all the SC mice) and the other 9 mice were monoallelic mutant. TA cloning and sequencing results of 5 biallelic mutant mice revealed that about 79% of the clones have insertion or deletion mutations (Figs. S6F and S6G and Table S4)
- Production of Mice Harboring sgRNA-Mediated Biallelic Mutations with DKO-AG-haESCs in One Step
- A. Construction of DKO-AG-haESCs with Constant Expression of Cas9 and sgRNA Library
- Initial cells: IGΔ
DMR -H19ΔDMR -AGH-1 - Specific construction of cell lines by Lenti-Cas9+lenti-sgRNA method: The construction was carried out following the method “co-infection with lentiviral Cas9+lentiviral sgRNA library” as described in Section 1.5.
- The cell line integrated with lentiviral Cas9 and lentiviral sgRNA library was further sorted by FACS to enrich the haploid cells for use in subsequent ICAHCI operation.
- B. Construction of Semi-Cloned Mice:
- Following the method as described in Section 1.9, semi-cloned mice were constructed by ICAHCI using DKO-AG-haESCs with constant expression of Cas9 and sgRNA library as a donor.
- Detection of allelic mutation: The detection was carried out following the method as described in Example 11.
- Exemplary primers for identifying the mutations in mice:
-
Polm check-F: TCCGATGGGAAGCCAAAAGC Polm check-R: CGTACCGCAACCGCGAAGTA Scube1 check-F: CCATAATAATCCACTTCCAT Scube1 check-R: CCAACCCCTGTCCACTACCT - C. Results
- In this experiment, DKO-AG-haESCs with constant expression of Cas9 and sgRNA library were obtained by two rounds of screening with drugs. SC mice were then generated by ICAHCI (
FIG. 5A-D ) (where this protocol was known as Lenti-Cas9+lenti-sgRNA). 272 (18.7%) of the 1,453 embryos reconstructed by ICAHCI were developed fully (FIG. 5E ) and the birth rate was basically similar to that obtained with WT DKO-AG-haESCs or DKO-AG-haESCs carrying different gene modifications (Table 2), indicating that after multiple genetic manipulations, the ability of DKO-AG-haESCs to produce SC mice is not affected. A total of 224 SC mice carried one sgRNA and were used for subsequent genotyping (FIG. 5F and Table 2). The results showed that 143 SC mice are genetically mutated, of which 83 are biallelic mutant mice (FIG. 5G ). 60 monoallelic mutant SC mice were obtained. Although Cas9 in these mice was supposed to be constantly expressed, silencing of the viral vector led to transcriptional silencing of Cas9 at different development stages of the SC mice. TA cloning and sequencing of 26 biallelic mutant SC mice showed that about 66.3% of the clones have insertion or deletion mutations (FIGS. 5H and I). In order to further determine the mutation efficiency throughout the body of the SC mice, the genetic mutations in different organs (comprising the brain, heart, kidney, liver and lung) of 4 SC mice were analyzed and all of these organs were found to have biallelic mutations. Finally, TA cloning and sequencing of different organs in one SC mouse carrying Scube1 mutation was performed. The results showed that about 80% of the clones have insertion or deletion mutations (FIG. 5J ). Interestingly, this SC mouse died within an hour after birth, consistent with previous reports that the Scube1 mutant mouse died shortly after birth (Tu, C. F., Yan, Y. T., Wu, S. Y., Djoko, B., Tsai, M. T., Cheng, C. J., and Yang, R. B. (2008). Domain and functional analysis of a novel platelet-endothelial cell surface protein, SCUBE1. The Journal of biological chemistry 283, 12478-12488). In conclusion, the above experimental results provide sufficient evidence for the possibility of obtaining a large number of mutant mice with DKO-AG-haESCs carrying the sgRNA library, thereby achieving the large-scale gene knockout-based screening at the mouse level, which greatly simplifies the DKO-AG-haESC-mediated gene knockout-based screening. -
TABLE 1 Summary of in-vivo development of ICAHCI embryos Number of growth-arrested Number of Number mice (% of normal mice Cell of number of (% of number Type of donor Haploid ES cell passage embryos embryos of embryos cells line number transferred transferred) transferred) Single DMR KO H19Δ DMR -AGHp8-pl7 1443 39 (2.7) 86 (5.9)c AG-haESCs Cells IGΔ DMR -AGUp8-p23 499 12 (2.4) 4 (0.8)d Cells DKO-AG- H19Δ DMR -IGΔDMR -pl9-p33 939 4 (0.4) 210 (22.4) haESCs AGH Cells IGΔ DMR -H19ΔDMR -p24-p28 544 5 (0.9) 105 (19.3) AGH Cells H19Δ DMR -IGΔDMR -p26-p37 510 1 (0.2) 87 (17.1) AGH-OG3 Cells Subtotal pl9-p37 1993 10 (0.5) 402 (20.2)e DKO-AG-ha Tet-TKO-DAH p35-p37 407 4 (1) 59 (14.5) ESCs carrying Cells Tel 1, 2 and 3 triple mutations DKO-AG-ha p53-TKO-DAH p41-p46 660 2 (0.3) 111 (16.7) ESCs carrying Cells p53, 63 and 73 triple mutations DKO-AG-ha Tet1&3-KI- p40-p47 138 1 (0.7) 21 (15.2) ESCs carrying DAH-1 Tet1 and 3 knock-ins DKO-AG-ha Tet-TKI-DAH-1 p47-p51 874 6 (0.7) 151 (17.3) ESCs carrying Tet1, 2 and 3 knock-ins WT AG-haESCs AGH Cellsa p9-p20 294 3 (1.0) 2 (0.7) AGH-OG-3 pl2-p26 379 6 (1.6) 7 (1.8) Cellsb Round spermatid 125 0 28 (22.4) aAG-haESCs: prepared according to the present invention. See Method 1.3. bAG-haESCs: derived from the prior art, supplied by the author of (Yang, H., Shi, L., Wang, B. A., Liang, D., Zhong, C., Liu, W., Nie, Y., Liu, J., Zhao, J., Gao, X., et al. (2012). Generation of genetically modified mice by oocyte injection of AG-haESCss. Cell 149, 605-617). cFor H19Δ DMR -AGR Cells, p < 0.05, compared with WT AG-haESCsdFor IGΔ DMR -AGU Cells, p > 0.05, compared with WT AG-haESCseFor DKO-AG-haESCs, p < 0.001, compared with WT AG-haESCs -
TABLE SI Summary of in-vivo development of ICAHCI embryos constructed with different AG-haESCs Number of growth-arrested Number of Number mice (% of normal mice Cell of number of (% of number Type of donor Haploid ES cell passage embryos embryos of embryos cells line number transferred transferred) transferred) H19-DMR H19Δ DMR -AGH-1p8 375 10 (2.7) 10 (2.7) KO p9 180 9 (5.0) 13 (7.2) AG-haESCs H19Δ DMR - AGH-2p8 210 5 (2.4) 6 (2.9) p9 116 2 (1.7) 4 (3.4) p11 123 3 (2.4) 3 (2.4) H19Δ DMR -AGH-3p8 271 1 (0.4) 29 (10.7) p17 168 9 (5.4) 21 (12.5) IG-DMR KO IGΔ DMR -AGH-1p14 84 0 0 AG-haESCs p15 100 4 (4) 0 p17 54 4 (7.4) 1 (1.9) p23 81 1 (1.2) 0 IGΔ DMR -AGH-2p8 180 3 (1.7) 3 (1.7) H19Δ DMR -H19Δ DMR -IGΔDMR -pl9 175 1 (0.6) 44 (25.1) IGΔ DMR -AGHAGH-1 Cells H19Δ DMR -IGΔDMR -pl9 245 2 (0.8) 56 (22.9) AGH-2 H19Δ DMR -IGΔDMR -p29 204 0 46 (22.5) AGH-3 H19Δ DMR -IGΔDMR -p29 165 1 (0.6) 32 (19.4) AGH-4 p33 150 0 32 (21.3) IGΔ DMR -H19ΔDMR -IGΔ DMR -H19ΔDMR -p24 120 1 (0.8) 26 (21.7) AGH Cells AGH-1 IGΔ DMR -H19ΔDMR -p24 180 2 (1.1) 47 (26.1) AGH-2 p28 244 2 (1.3) 32 (22.2) IGΔ DMR -H19ΔDMR -IGΔ DMR -H19ΔDMR -p26 118 0 17 (14.4) AGH-OG3 AGH-OG3-1 Cells IGΔ DMR -H19ΔDMR -p30 192 1 (0.5) 36 (18.8) AGH-OG3-2 p37 200 0 34 (17) WT AGH-OG-3a p12 82 0 1 (1.2) AG-haESCs p20 93 4 (4.3) 0 p24 140 2 (1.4) 5 (3.6) p26 64 0 1 (0.9) AGH-2b p19 114 0 1 (0.9) p20 62 3 (4.8) 0 AGH-3c p9 118 0 1 (1.2) aAG-haESCs: made according to the prior art. bAG-haESCs: derived from the prior art (Yang, H., Shi, L., Wang, B. A., Liang, D., Zhong, C., Liu, W., Nie, Y., Liu, J., Zhao, J., Gao, X., et al. (2012). Generation of genetically modified mice by oocyte injection of androgenetic haploid embryonic stem cells. Cell 149, 605-617) -
TABLE S3 Summary of in-vivo development of ICAHCI embryos constructed with genetically modified DKO-AG-haESCs Number of growth-arrested Number of Number mice (% of normal mice Cell of number (% of number Type of donor Haploid ES passage embryos of embryos of embryos cells cell line number transferred transferred) transferred) DKO-AG-ha ESCs Tet-TKO-DAH-1 p37 131 2 (1.5) 17 (13) Carrying Tet1, 2 Tet-TKO-DAH-2 p37 54 0 9 (16.7) and 3 Mutations Tet-TKO-DAH-3 p36 174 1 (0.6) 27 (15.5) Tet-TKO-DAH-4 p35 48 1 (2.1) 6 (12.5) DKO-AG-ha p53-TKO-DAH-l p42 182 1 (0.5) 34 (18.7) ESCs carrying p53, p44 186 0 32 (17.2) p63 and p73 p53-TKO-DAH-2 p41 154 0 23 (14.9) mutations p42 48 1 (2.1) 8 (16.7) p53-TKO-DAH-3 p46 90 0 14 (15.6) DKO-AG-haESCs Tet1&3-KI- p40 58 1 (1.7) 10 (17.2) carrying Tet1 and 3 DAH-1 p47 80 0 11 (13.8) knock-ins DKO-AG-ha ESCs Tet-TKI-D p47 48 1 (2.1) 8 (16.7) carrying Tet1, 2 AH-1 p49 174 0 32 (19) and 3 knock-ins Tet-TKI-D p47 96 3 (3) 10 (10.4) AH-2 p50 136 1 (0.7) 22 (16.2) Tet-TKI-D AH-3 p49 48 0 8 (16.7) Tet-TKI-D AH-4 p50 102 1 (1.0) 14 (13.7) Tet-TKI-D AH-5 p51 174 0 39 (22.4) Tet-TKI-D AH-6 p51 96 0 18 (18.8) -
TABLE 2 Summary of in-vivo development of ICAHCI embryos constructed with DKO-AG-haESCs carrying sgRNA library Number of SC Number Number Number Number of Number of mice of SC of SC of SC SC mice SC mice Number of (% of number mice mice with mice with with with embryos of embryos without sgRNA one biallelic monoallelic Strategy transferred transferred) sgRNA (n > 2) sgRNA mutation mutation Lenti- 580 114 (19.7) 11 21 82 0 43 sgRNA+ pX330 Lenti- 306 51 (16.7) 0 4 47 12 10 sgRNA+ Cas9 injection Lenti-sgR 238 31 (13.5) 3 1 27 13 9 NA+pX330+ Cas9 injection Lenti-Cas 1453 272 (18.7) 22 13 237 83 60 9+lenti- sgRNA - The above examples are provided for the purpose of illustrating the embodiments disclosed in the present invention and are not to be construed as limiting the present invention. In addition, various modifications and variations of the methods and compositions made without departing from the scope and spirit of the present invention are apparent to those skilled in the art. While the present invention has been specifically described in connection with various specific preferred embodiments thereof, it is to be understood that the present invention is not limited to these specific embodiments. In fact, various apparent modifications made to the present invention as described above are embraced in the scope of the present.
-
Sequence listing <110> Shanghai Institutes for Biological Sciences Chinese Academy of Sciences <120> Androgenetic haploid embryonic stem cell (AG-haESC), and preparation method and use thereof <130> 140709 <160> 16 <170> PatentIn version 3.3 <210> 1 <211> 20 <212> DNA <213> Artificial <220> <223> IG-DMR-sgRNA1 sequence <400> 1 cgtacagagc tccatggcac 20 <210> 2 <211> 20 <212> DNA <213> Artificial <220> <223> IG-DMR-sgRNA2 sequence <400> 2 ctgcttagag gtactacgct 20 <210> 3 <211> 20 <212> DNA <213> Artificial <220> <223> H19-3.8K sgRNA-1 sequence <400> 3 catgaactca gaagagactg 20 <210> 4 <211> 20 <212> DNA <213> Artificial <220> <223> H19-3.8K sgRNA-2 sequence <400> 4 aggtgagaac cactgctgag 20 <210> 5 <211> 20 <212> DNA <213> Artificial <220> <223> Tet1 sgRNA sequence <400> 5 ggctgctgtc agggagctca 20 <210> 6 <211> 20 <212> DNA <213> Artificial <220> <223> Tet2 sgRNA sequence <400> 6 gaaagtgcca acagatatcc 20 <210> 7 <211> 20 <212> DNA <213> Artificial <220> <223> Tet3 sgRNA sequence <400> 7 aaggagggga agagttctcg 20 <210> 8 <211> 20 <212> DNA <213> Artificial <220> <223> p63 sgRNA sequence <400> 8 cacctgggct tcctgcagtc 20 <210> 9 <211> 20 <212> DNA <213> Artificial <220> <223> p63 sgRNA sequence <400> 9 tgggcccggg taatctgtgt 20 <210> 10 <211> 20 <212> DNA <213> Artificial <220> <223> p73 sgRNA sequence <400> 10 tgtcgatagg agtcaaccaa 20 <210> 11 <211> 895 <212> DNA <213> Artificial <220> <223> Sequence of TET1 LA left homologous arm <400> 11 aagcttaagg ttcacacaac actaagagct tttcatcagc ctcatctact tctcacctag 60 tgaaagacga atctacagac ttctgtcccc tgcaggcttc ctccgcagaa acatctacct 120 gtacgtacag taaaacagcc tcaggtgggt ttgcagaaac aagtagtatt ctccactgca 180 caatgccttc tggagcacac agtggtgcta atgcagctgc tggggaatgt actggaacgg 240 tgcagcctgc cgaggtggct gctcatcctc accagtctct tcccacagcc gattctcccg 300 ttcatgctga gcctctcact agtccatctg agcagctaac ttctaaccag tcaaaccagc 360 agctccctct cctcagcaat tctcagaaac tggcttcctg tcaggtggaa gatgagcggc 420 accctgaagc ggatgagcct cagcaccccg aggacgataa cttgcctcaa cttgatgaat 480 tctggtcaga cagtgaggag atctacgccg atccttcctt tggtggcgtg gcgatagcac 540 ccattcacgg ctcggtgctc attgagtgcg ctcggaagga gettcatgct accacctctt 600 tgcgctcccc caaacgaggg gtcccttttc gtgtgtccct tgtattctac cagcacaaaa 660 gcctaaacaa gcctaatcat ggttttgata tcaacaaaat taagtgtaaa tgcaaaaaag 720 taacgaaaaa aaagcccgca gaccgggagt gtcctgatgt atcccccgaa gccaatttat 780 cacaccaaat tccttctcga gttgcatcaa ccttaacccg agacaatgtt gttaccgtgt 840 ccccatactc tctcactcat gttgcgggac cctacaatcg ttgggtcgcg tcgac 895 <210> 12 <211> 803 <212> DNA <213> Artificial <220> <223> Sequence of TET1 RA right homologous arm <400> 12 taaaggcttc tctcatgtaa tgcctttgct aatgtggtgt agtgggtatt tttgtttgtt 60 tgtttgtttt cttttgtttt tttgtttttt ccggtgctgt taaaaagaaa gtcattctgt 120 tgtttactgt agctttgttt cgcccatttc aactccgacg taaatattaa aaaaaaaaaa 180 agggtgaata cttaactgtg attacatttt gagaattggt agaaggtgaa cattttcagc 240 aaaaataaac tttttatagt tttaaatact taaaggaaca tcttggttag gtgttggcca 300 tgctagaacc atagagtctg gtgctttccc ccgggtttgt ttactattca gagggtttat 360 aacaggttcc tgcaataaga agtaaagacc aagatgtagt gttaactcta cacagttcct 420 ggtgctttaa ccacatcaac acacggagtg atgagctgag tgattgtttt ctggtgccat 480 tgctcaagcc tcttccaatc attgccatcg tgtctgcaca tttctttgaa gtaaaccaat 540 gaaatgcttt ttctcttaaa acatttctcc tatataaagt agttctctat tctcatgatg 600 gttggaagct gttcgctaac tataaatgta tatattttaa aaagcacttt ttacttttaa 660 gagtaacttg aaatagtata gtagcagaat cctattgtct attatgtgtg catatttgaa 720 taccagagaa gtcatttgtt cttgctctgt agagtcccat cccgttaacc tcagcctgta 780 ctcaaataac acacggcttc tgt 803 <210> 13 <211> 809 <212> DNA <213> Artificial <220> <223> Sequence of TET3 LA left homologous arm <400> 13 ctggtcccag cctaactgag aagtcatggg ggatgggaac cggggatttc aacctcgccc 60 tgaaaggtgg acctgggttc caagacaagt tgtggaatcc tgtgaaggtg gaggagggca 120 ggattcccat accgggggcc aactcgctag acaaagcctg gcaagccttt ggcatgccct 180 tgagctccaa cgagaagcta tttggggccc tgaagtcaga ggagaaactg tgggatccct 240 tcagcctgga ggaggggaca gctgaggagc cccccagcaa gggggtggtg aaggaagaga 300 agagtggacc cacagtgaaa gaggacgagg aggaactgtg gtcggacagt gaacacaact 360 tcctggatga gaacataggc ggggtggccg tggccctcgc ccattgctcc atcctcatcg 420 agtgtgcccg gcgagagctg catgccacca ctccactcaa aaaacccaac cgctgccacc 480 ccacccgcat ctcgctggtc ttctaccaac acaagaacct caaccagtcc aaccacgggc 540 tggcgctctg ggaggccaag atgaagcagc tggcggaatg ggcgcggcag cggcaagagg 600 aggccgcacg cctgggcctg ggccagcagg aggccaagct ctacgggaag aagcgaaaat 660 gggggggtgc tatggtggct gagccccagc aeaaagaaaa gaagggggct atccctaccc 720 ggcaggcgct ggccatgccc acagacttcg cggtcaccgt gtcctcttac gcctacacaa 780 aggtcactgg cccctacagc cgctggatc 809 <210> 14 <211> 837 <212> DNA <213> Artificial <220> <223> Sequence of TET3 RA right homologous arm <400> 14 taggtgccag gagccagcgt acctcagcgt cgggcccggc ccgagctgct ctgtggtgct 60 tttgccctca tgcccggggg cgggttgggg gtgcagaagt ctctctatat ctacatatat 120 ggatatgctt atcatatata tgtatttatg gtccaaacct cagaactgac ccgccctccc 180 tcctcttctt ccccagcact ttgaagaaac tacggctgtc gggtgatttt tttttttttt 240 tgatcttaat atttatatct ccacgtttta tttttcccct tgttttgagg gggcttttat 300 tttccttttg tttttaaaac tttatccttg tatatcacaa taatggaaag aaagtttata 360 gtgtcctttc acaaaggagc gtagttttaa aattccattt aaaatatgta tttattgggt 420 ttttttaaag caacaatagt aatgggttac aggtgggcag gaaaggccgg cagtgcttcc 480 tgcctggcaa gcccagcctc ctgggggctg caggctctct cagccatctg cctcacaaac 540 caaggttagc atgtagccct ggtttatccc tccttcccac aggctgggga gccttttggg 600 accaccccgt tctcctctgt ggaatggggg aagctgcaga catctggggg cctggcctgg 660 aaatgctggt gttagatatc cccagaaacc aggttggaag tagacagctt caagcttgct 720 agtctccaca ctgaatcctc tctgtccgtt atttaccaag tcatatgatg tcctggttcg 780 ctaggcagca cctcaagctg gagcaggagt cgagaggctc cgaggagctc ttctcgt 837 <210> 15 <211> 824 <212> DNA <213> Artificial <220> <223> Sequence of TET2 LA left homologous arm <400> 15 caaatgtaca ccacctagca acgttttctc cttaccccac coccaagatg gatagtcatt 60 tcatgggagc tgcctccaga tcaccataca gccacccaca cactgactac aaaaccagtg 120 agcatcatct accctctcac acgatctaca gctacacggc agcagcttcg gggagcagtt 180 ccagccacgc cttccacaac aaggagaatg acaacatagc caatgggctc tcaagagtgc 240 ttccagggtt taatcatgat agaactgctt ctgcccaaga actattatac agtctgactg 300 gcagcagtca ggagaagcag cctgaggtgt caggccagga tgcagctgct gtgcaggaaa 360 ttgagtattg gtcagatagt gagcacaact ttcaggatcc ttgcattgga ggggtggcta 420 tagctccaac tcatgggtca attcttattg agtgtgcaaa gtgtgaggtt catgccacaa 480 ccaaagtaaa cgatcccgac cggaatcacc ccaccaggat ctcacttgta ctgtataggc 540 ataagaattt gtttctacca aaacattgtt tggctctctg ggaagccaaa atggctgaaa 600 aggcccggaa agaggaagag tgcggaaaga atggatcaga ccacgtgtct cagaaaaatc 660 atggcaaaca ggaaaagcgt gagcccacag ggccacagga acccagttac ctgcgtttca 720 tccagtctct tgctgagaac acagggtctg tgactacgga ttctaccgtg actacatcac 780 catatgcttt cactcaggtc acagggcctt acaacacatt tgta 824 <210> 16 <211> 792 <212> DNA <213> Artificial <220> <223> Sequence of TET2 RA right homologous arm <400> 16 tgacgctggc cattaggcca gaccaccaag gacgacctgt gagcagtatg tctttcatgg 60 catgggccgt agggacaggt cacagcatct gtgacaaatg cagtgtgtgt ttgtgtgtat 120 gtttattggg ggggggctgt cagctcacca gcaaaatagt ttattttatc attatattta 180 atctctcccg tggtccatgg tggcattcag gaagagcatc ctatgcaagg gcacagtggg 240 aaggaagcgc tggacatttg tcttgaaaac cactggttct cttattggct gaggtcatgc 300 gtgtgccatg cccctcagca ctctacacgt aactgcttct agtattcagc gtgtgtaacc 360 gtgggacaca gcgctgtagt agagcagttg caggatcatc tggtgctgac gtatgatgta 420 ctgaagaaat actggaacta agacttttta acatgcaggt tttttactgt aatcttaata 480 acttatttat caaagtagct acagaaagct taagtgaata atggcaaaac actgaatctg 540 tttgggtgtt aacattaaat ggtgctacaa atggtgtttt taatagctga aaaatcaatg 600 ccttctatca tctagccagt gtggtcgagg gccctggagg cactggggta cctctgattt 660 tacatttcta tcttaattat tcagcttagt ttttaaaatg tggacatttc aaaggcctct 720 ggattgtagt tatccaccga tgtccttgta ggactataat gtatagatat gcacacttac 780 acatgtgtac tg 792
Claims (17)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2015/083165 WO2017000302A1 (en) | 2015-07-02 | 2015-07-02 | Androgenetic haploid embryonic stem cell, and preparation method and use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
US20180251728A1 true US20180251728A1 (en) | 2018-09-06 |
US11330806B2 US11330806B2 (en) | 2022-05-17 |
Family
ID=57607612
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/740,974 Active 2037-03-23 US11330806B2 (en) | 2015-07-02 | 2015-07-02 | Androgenetic haploid embryonic stem cell (AG-HAESC), and preparation method and use thereof |
Country Status (4)
Country | Link |
---|---|
US (1) | US11330806B2 (en) |
EP (1) | EP3318639A4 (en) |
CN (1) | CN108368519A (en) |
WO (1) | WO2017000302A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN118370275A (en) * | 2024-06-21 | 2024-07-23 | 中国科学院昆明动物研究所 | Method for producing maternal half-cloned mice |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110095610A (en) | 2018-01-31 | 2019-08-06 | 中国科学院上海生命科学研究院 | A kind of high throughput protein analysis method and its applicable library |
CN112680407B (en) * | 2019-10-17 | 2023-03-31 | 中国科学院分子细胞科学卓越创新中心 | Compound for promoting muscle stem cell differentiation and application thereof |
CN114107398B (en) * | 2020-08-27 | 2023-11-03 | 中国科学院分子细胞科学卓越创新中心 | Construction method and application of point mutation animal model of dentin hypoplasia |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013143467A1 (en) * | 2012-03-27 | 2013-10-03 | 中国科学院上海生命科学研究院 | Androgenetic haploid stem cell line, preparation method and use thereof |
GB2500933A (en) | 2012-04-05 | 2013-10-09 | John Stephen Rubin | Artificial syrinx comprising a fenestrated tracheostomy tube |
WO2013159313A1 (en) * | 2012-04-26 | 2013-10-31 | 中国科学院动物研究所 | Animal embryonic stem cell line, and preparation method and application thereof |
-
2015
- 2015-07-02 CN CN201580024974.6A patent/CN108368519A/en active Pending
- 2015-07-02 US US15/740,974 patent/US11330806B2/en active Active
- 2015-07-02 EP EP15896833.9A patent/EP3318639A4/en active Pending
- 2015-07-02 WO PCT/CN2015/083165 patent/WO2017000302A1/en active Application Filing
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN118370275A (en) * | 2024-06-21 | 2024-07-23 | 中国科学院昆明动物研究所 | Method for producing maternal half-cloned mice |
Also Published As
Publication number | Publication date |
---|---|
WO2017000302A1 (en) | 2017-01-05 |
CN108368519A (en) | 2018-08-03 |
US11330806B2 (en) | 2022-05-17 |
EP3318639A1 (en) | 2018-05-09 |
EP3318639A4 (en) | 2018-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zuo et al. | CRISPR/Cas9-mediated targeted chromosome elimination | |
Zhong et al. | CRISPR-Cas9-mediated genetic screening in mice with haploid embryonic stem cells carrying a guide RNA library | |
CN106676075B (en) | Parthenogenetic haploid embryonic stem cell and preparation and application thereof | |
Zhang et al. | Comparison of gene editing efficiencies of CRISPR/Cas9 and TALEN for generation of MSTN knock-out cashmere goats | |
JP2023054185A (en) | Method for manufacturing dna-edited eukaryotic cell and kit used in that method | |
US12041918B2 (en) | Production of fertile XY female animals by silencing of genes on the Y chromosome | |
US12037601B2 (en) | Method of inactivating a FEL D1 gene using crispr | |
US20190223417A1 (en) | Genetically modified animals having increased heat tolerance | |
US11330806B2 (en) | Androgenetic haploid embryonic stem cell (AG-HAESC), and preparation method and use thereof | |
Li et al. | Temporal regulation of prenatal embryonic development by paternal imprinted loci | |
WO2020198541A1 (en) | Porcine reproductive and respiratory syndrome virus (prrsv) resistant swine | |
US20230167443A1 (en) | Optimised Methods for Cleavage of Target Sequences | |
CN113801851A (en) | Somatic cell nuclear transplantation method and application thereof | |
González-Martínez et al. | miR-203 controls developmental timing and early fate restriction during preimplantation embryogenesis | |
王乐韵 et al. | Overcoming Intrinsic H3K27me3 Imprinting Barriers Improves Post-implantation Development after Somatic Cell Nuclear Transfer | |
Chen | Development and Application of Genome Editing Approaches to Investigate Endogenous Retroviruses | |
李伟 et al. | Genetic Modification and Screening in Rat Using Haploid Embryonic Stem Cells | |
NZ740899B2 (en) | Selection of pluripotent cells for production of fertile xy female mice |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
AS | Assignment |
Owner name: SHANGHAI INSTITUTES FOR BIOLOGICAL SCIENCES, CHINESE ACADEMY OF SCIENCES, CHINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LI, JINSONG;WU, YUXUAN;ZHONG, CUIQING;AND OTHERS;REEL/FRAME:046162/0386 Effective date: 20180201 Owner name: SHANGHAI INSTITUTES FOR BIOLOGICAL SCIENCES, CHINE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LI, JINSONG;WU, YUXUAN;ZHONG, CUIQING;AND OTHERS;REEL/FRAME:046162/0386 Effective date: 20180201 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
AS | Assignment |
Owner name: CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE, CHINESE ACADEMY OF SCIENCES, CHINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SHANGHAI INSTITUTES FOR BIOLOGICAL SCIENCES, CHINESE ACADEMY OF SCIENCES;REEL/FRAME:053823/0871 Effective date: 20200710 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |